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ABSTRACT
Role of Protein Kinase C Isoforms in Human Breast Tumor Cell Survival
Meredith A. McCracken
Protein kinase C (PKC) is a family of serine/threonine kinases composed of 12 unique
isoforms that function in a variety of cellular processes including proliferation, apoptosis,
differentiation and carcinogenesis. The contribution of individual PKC isoforms to these
processes is largely unexplored. The purpose of this study is to identify specific PKC
isoforms that promote breast tumor cell survival following radiation treatment. This work
demonstrated that depletion of PKC d and PKC z isoforms from MCF-7 and MDA-MB-
231 human breast tumor cells by antisense oligonucleotides significantly impaired
survival following radiation insult. Antisense oligonucleotides were shown to be effective
and selective inhibitors of specific PKC soforms. The PKC d inhibitor, rottlerin reduced
cell survival and confirmed that PKC d inhibition attenuates breast tumor cell survival,
both in the presence and absence of radiation insult. Inhibition of PKC z significantly
reduced the survival of radiation treated breast tumor cells. DNA damage, assessed using
the comet assay provided evidence that depletion of PKC d from MDA-MB-231 cells
results in loss of DNA integrity. In contrast, PKC z antisense oligonucleotide treatment
did not result in DNA damage. Consistent with participation in cell survival, PKC d
protein levels were elevated in response to radiation treatment. These studies have
identified two PKC isoforms that function in breast tumor cell survival and support the
application of isoform specific PKC inhibitors to the treatment of human breast tumors.
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1I. INTRODUCTION
1. Breast Cancer
   Women in the United States have a one in eight (12%) relative lifetime risk for the
development of breast cancer, the most frequent form of cancer in women. Breast cancer
incidence in the U.S. has steadily risen since the 1930's, by an average increase of 1.2% per year.
In the year 2001, breast cancer is predicted to affect 192,000 women, resulting in death for
40,000 women in the U.S. alone. Additionally, 1500 men will be diagnosed with breast cancer in
the U.S. The first significant reduction in breast cancer mortality rates was observed in data from
the 1990-1997 period and is probably due to improved therapies and earlier detection (Cancer
Facts and Figures 2001, American Cancer Society).
    The therapeutic benefits of single agents are often improved upon by utilizing combinations of
treatment modalities. The purpose of this dissertation was to improve breast cancer therapy by
increasing the effectiveness of radiation therapy through a novel approach. Protein kinase C
(PKC) has been a relatively understudied target for r diosensitization. Our approach to enhance
radiation therapy was through the inhibition of PKC. The intent of this introduction is to provide
a brief overview of the underlying genetic factors in breast cancer and current breast cancer
treatment strategies as well provide an understanding of radiation biology and PKC.
2. Genetic Susceptibility
   Breast cancer susceptibility is a culmination of several different risk factors including age,
family history, obesity, menstrual history, pregnancy, oral contraceptive use, diet and alcohol
consumption. The single most important factor in breast cancer risk assessment is family history.
A positive family history may be a consequence of inherited germ-line mutations in genes which
2result in a predisposition to breast cancer. Table 1 provides a summary of inherited mutations
that produce breast cancer susceptible phenotypes.
    Early studies sought to identify a 'breast cancer susceptibility gene' and suggested that the
autosomal dominant inheritance of a gene on chromosome 17 was partly responsible for the
predisposition to breast cancer (Lynch et al., 1972). The location of the gene was narrowed to the
q12 region on chromosome 17 and identified as BRCA1(Miki et al., 1994). Linkage analysis
studies conducted on families with early-onset breast cancer revealed linkage between BRCA1
and early-onset breast cancer in 45% of the families (Easton et al., 1993). To determine the
penetrance of the BRCA1 mutation, breast cancer incidences in families carrying the BRCA1
mutation were observed. The penetrance of the BRCA1 mutation increases with age and by age
70 years is estimated to be 85% (Easton et al., 1995).
      Since mutations in BRCA1 account for only half of familial breast cancers and do not seem to
be linked to male breast cancer, there may be other genes which contribute to breast cancer
predisposition. Genetic linkage analysis was performed on families with early-onset breast
cancer, who had no evidence of BRCA1mutation. A second gene, BRCA2, was identified on
chromosome 13q (Wooster et al., 1995). Like BRCA1, BRCA2 is a highly penetrant mutation
with 80% of the females who carry the mutation, afflicted with the disease by age 70. Males
carrying the BRCA2 mutation are estimated to have a 6% risk over the general population for
developing breast cancer by age 70 years (Easton et al., 1995). More recent findings have
supported the contribution of BRCA2 mutation to male breast cancer (Csokay et al., 1999).
   BRCA1 and BRCA2 mutation show a pattern similar to that observed in tumor suppressor genes
such as retinoblastoma (Rb) and p53. Individuals inheriting a germ-line mutation in BRCA1 or 2
are heterozygous at these particular loci, with one normal and one mutant allele. A predisposition
3to breast cancer is dependent on a loss of heterozygosity at the BRCA1/2 loci, which occurs by
acquisition of a somatic mutation in the remaining normal allele of BRCA1/2. An important
distinction between classic tumor suppressor genes and BRCA1/2 is that the latter is thought not
to directly promote tumor initiation but genomic instability (Kinzler and Vogelstein, 1997).
Genetic instability facilitates the accumulation of somatic mutations, including mutations in
genes, which may directly regulate cell division and death, thus resulting in tumor initiation.
   More recently an additional gene that confers breast cancer susceptibility was identified. The
cell cycle checkpoint kinase, Chk2, is involved in response to DNA damage and is thought to
participate in the same pathway as BRCA1 and p53. A deletion within the CHK2 ge e r sulting
in a truncated, non-functional protein was observed in 5% of individuals with breast cancer
(Meijers-Heifboer t al., 2002). Estimates indicated that female carriers of this mutation have a
twofold greater risk over the general population of developing breast cancer, while male carriers
have a tenfold increased risk. Unlike BRCA1 and BRCA2, the CHK2 mutation has relatively low
penetrance. However, these findings are significant because the prevelance of the CHK2
mutation in the general population is much higher (1.1%) than the estimated frequency of
BRCA1/2 mutations (0.12-0.29%) in the general population (Iau et al., 2001).
    Homozygous mutation of the ataxia-tel ngiectasia (AT) gene produces the AT syndrome.
Individuals with AT have a 100-fold increased risk for the development of cancer. Carriers of the
AT gene mutation (heterozygotes) are not affected by the AT autosomal recessive syndrome but
still have a higher risk for the development of cancer. Breast cancer is the most frequently
associated form of cancer in heterozygous AT mutant individuals. Estimates predict that 30% of
all female AT carriers will develop breast cancer by age 70. Furthermore, an elevated risk of
male breast cancer is correlated with AT mutation carriers (Couch and Weber, 2001).
4   Multiple other genetic disorders have been related to an increased probability for the
development of numerous forms of cancer, including breast. The predominant forms of cancer
experienced by individuals with Li-Fraumeni syndrome and their first degree relatives are soft
tissue sarcomas, bone and breast cancers. The underlying genetic defect in Li-Fraum ni
syndrome is mutation of the p53 tumor suppressor gene. Furthermore, mutation of the PTEN
tumor suppressor gene, the Cowden's disease susceptibility gene, is associated with an increased
risk to breast cancer. Cowden's disease is characterized by autosomal dominant inheritance of the
mutant PTEN. Breast cancer has been observed in 30% of women with Cowden's disease (Iau et
al., 2001). Cancer risk, including breast, is elevated in individuals with Muir-Torre and Peutz-
Jeghers syndromes. These syndromes display autosomal dominant modes of inheritance and are
linked to mutations in DNA mismatch repair genes (MLH1/MSH2) and a serine-threonine kinase
(STK11), respectively (Couch and Weber, 2001). Lastly, the rare au osomal recessive disorder,
Bloom syndrome, is accompanied by an increased incidence of breast cancer as well as
leukemia, lymphoma and colon carcinomas. The underlying pathology of this disorder is not
well characterized, but thought to be due to homozygosity at a particular locus on chromosome
15 that results in genomic instability.
5Table 1. Inherited breast cancer susceptibility
Gene                 Function                             Penetrance              Associated Syndrome
BRCA1
BRCA2
AT
P53
PTEN
MLH1/MSH2
STK 11
Chromosome 15
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
DNA Repair
Signal Transduction
85%*
80%*
30%*
15%
30%
N/A
18%
4%
None
None
Ataxia Telangiectasia carriers
Li-Fraumeni
Cowden’s
Muir-Torre
Peutz-Jehgers
Bloom
*Indicates penetrance for women by age 70 years. The remaining p netrance estimates were
derived  from observations of breast cancer incidence within groups of women (Cowden’s) or
men and women (Peutz-Jehgers and Bloom) of varied ages affected with the syndromes.
63. Somatic Mutations in Breast Cancer
   A large portion (90-95%) of breast cancer incidences are not inherited but sporadic (American
Medical Association, 2001). The somatic alterations present in breast cancer cells include
amplifications, deletions and mutations. The carcinogenesis of breast cancer is a multi-step
process, however the sequence of the genetic events leading to tumor progression is not clear.
Somatic mutations in the BRCA1 and BRCA2 genes are rare, while inheritance of either is
associated with an increased number of somatic mutations in other genes. This section will
discuss the modifications of receptors, cell cycle regulators, transcription factors, signaling and
cell adhesion molecules caused by known genetic alterations in breast cancer. Table 2 may be
referred to for a summary of frequent somatic alterations observed in breast cancers.
   Among the numerous genes with aberrant expression in breast cancer, the most frequent is the
E-cadherin, CDH1 gene. An estimated 60-70% of breast tumors display reduced or absent E-
cadherin protein expression (R mm et al., 1995; Palacios et al., 1995). E-cadherin is a calcium-
dependent protein that functions in epithelial cell-cell interactions within normal adult mammary
tissue. Reduced expression or loss of function of this cell adhesion molecule may facilitate
invasive tumor cell growth. Nonsense and frameshift mutations in the CDH1 gene produce
truncated, non-immunohistochemically detectable E-cadherin protein molecules (B rx et al.,
1995).
   The p53 tumor suppressor gene is mutated in half of all human cancers and in 15-34% of breast
cancers (Ingvarrson, 1999). P53 provides an example of a gene in which mutation may be
inherited or sporadic. The majority of the somatic p53 u ations are missense mutations created
by a transversion of guanine:cytosine to hymine:adenine nucleotides. This transversion results in
an amino acid substitution that for which produces a dominant negative or dysfunctional p53
protein (Saitoh et al., 2001). P53 is a transcription factor that regulates the G1 checkpoint of the
7cell cycle. A function of p53 in response to DNA damage is transcriptional activation of the
cyclin-dependent kinase inhibitor, p21, which halts cell cycle progression. At this pause in the
cell cycle, DNA damage may be repaired or if damage is beyond repair, p53 may induce
apoptosis via transcriptional activation of the bax apoptotic gene (Dahm-Daphi, 2000). In the
absence of normal p53 function, cells may be allowed to progress to S-phase in spite of DNA
damage, resulting in propagation of cells containing damaged DNA. In addition, the positive cell
cycle regulator, cyclin D1, is reported to be amplified in 17% of breast tumors (Champeme et al.,
1995).
    Epidermal growth factor receptors (EGFR) are a family of receptor tyrosine kinases with
proto-oncogenic properties.  The EGFR and erbB-2 or HER-2/neu family members are
reportedly overexpressed in 20-40% of breast cancers (Couch and Weber, 2001; Clark and
McGuire, 1991). Increased expression results from amplification of the EGFR and HER-2/neu
genes. Detection of HER-2/neu protein overexpression by immunohistochemisty correlated with
gene amplification by fluorescence in situ hybridization (FISH) analysis (Lehr, 2001).
Overexpression of either receptor leads to misregulation of signal transduction pathways and cell
proliferation. Adapter proteins (Grb2 and Sos) couple HER-2/neu with the ras oncogene.
Increased expression of HER-2/neu manifests in aberrant activation of r s and the downstream
mitogen-activated protein kinase (MAPK) signal transduction pathway (J nes, 1994). While
dysregulation of ras signal transduction pathways is common in breast cancer, ras mutation
occurs in only approximately 5% of breast cancers (Clark and Deer, 1995).
    Estrogen and progesterone receptors play an important role in the function of the mammary
gland as well as in the development and progression of breast cancer. The absence of estrogen
and progesterone hormone receptors (ER and PR, respectively), a feature in 1/3 of breast cancer
cases, is associated with hormone independent growth, a less differentiated tumor phenotype and
8poor prognosis (Lapidus et al., 1998). Alternatively, breast tumors that express the estrogen and
progesterone receptors and retain hormone responsiveness have a better clinical outcome.
Numerous genetic aberrations in both the estrogen and progesterone receptors are reported
including point mutations and deletions that may alter receptor function, but generally do not
result in a loss of expression. Evidence suggests that loss of expression is due to gene silencing
through epigenetic modification of chromatin structure. Methylation of CpG islands within the
ER promoter and first exon was observed in 25% of ER-negative breast tumor cells (Ottaviano et
al., 1994). Subsequently, ER expression was rescued in ER-negative cells by treatment with
demethylating agents (Ferguson et al., 1995). As in the case of the ER, CpG island methylation is
a possible explanation for the loss of the PR receptor expression as well. Studies revealed a
correlation between CpG island methylation within the PR promoter and first exon in
approximately 40% of PR-negative breast tumor cells examined (Lapidus et al., 1996). Although,
deletions, insertions, polymorphisms and rearrangements have been observed in the ER an  PR
genes, they are rare and not associated with ER and PR loss in breast cancer. Methylatio  of
CpG islands is a feature shared by ER- and PR-negative br ast cancers and is at least one
mechanism for loss of receptor expression.
   The c-myc proto-oncogence is a transcription factor that promotes cell proliferation as well as
apoptosis. The principal role of c-Myc in cell proliferation is thought to involve transcriptional
activation of genes which positively regulate the cell cycle and/or transcripti nal repression of
negative regulatory cell cycle genes (Liao and Dickson, 2000). Amplification of the c-myc gene
is observed in approximately 18% of breast carcinoma biopsy specimens (Garcia et al., 1989;
Berns et al., 1992). Inconsistent with amplification being the only means of increased c-Myc
protein levels, c-Myc protein is reported to be verexpressed in 50-100% of breast cancer cases
(Liao and Dickson, 2000). Rearrangements of the c-myc locus have been reported in a small
9percentage of breast tumors (B nilla et al., 1988). Despite the lack of a clearly defined
underlying genetic mechanism, c-yc aberration appears to be important in the
initiation/progression of breast cancer.
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Table 2. Frequent somatic mutations in breast cancer
Gene               Product           Gene Alteration       Consequence (protein)     Prevela ce
CDH1
P53
EGFR&
HER-2/neu
MYC
PRAD1
E-cadherin
P53
EGFR&
HER-2/neu
Myc
CyclinD1
Reduced/Absent
Non-functional
Overexpression
Overexpression
Overexpression
60-70%
15-34%
20-40%
18%
17%
Non-sense/Frameshift
Missense (G    T)
Amplification
Amplification
Amplification
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4. Breast Cancer Treatment
   Current breast cancer treatment modalities include surgery, radiation and adjuvant therapies.
The two major surgical options for local tumor control are lumpectomy and masectomy. Surgical
removal of only the tumor with preservation of healthy breast tissue or lumpectomy, is followed
by daily doses of 1.8-2 Gy radiation for 5 to 6 weeks to reduce the risk of local recurrence (Perez
and Brady, 1992). Radiation therapy may be advised following masectomy in patients with
advanced primary or node positive breast cancer to prevent local recurrence. Surgical
oophorectomy (removal of ovaries) following local tumor control may be used to reduce the risk
of systemic recurrence in pre-menopausal women.
   Adjuvant therapies are used to reduce systemic recurrence risk depending on the stage of the
disease and post-menopausal status of the patient. In ti ts with large tumors and/or nodal
involvement, hormonal or chemo adjuvant therapies are usually prescribed. Tamoxifen, an anti-
estrogen, is an djuvent therapy option for tumors that are estrogen receptor (ER) positive, while
ER negative tumors are treated with chemo adjuvant therapy (NIH Consensus Statement, 2000;
Couch and Weber, 2001).
5. Radiation Therapy
5.1 Radiation Biology
   The goal of radiation therapy is to precisely deliver a measured dose of radiation to a defined
tumor resulting in tumor eradication with minimal damage to healthy tissue surrounding the
tumor. For breast cancer therapy, radiation is used as a companion to surgical tumor excision.
The effectiveness of radiation may be expressed in terms of the fraction of cells which survive
the dose of radiation. Mammalian cell survival curves form a characteristic shape (Figure 1). In
contrast to bacteria that for which have a linear slope, mammalian cell radiation survival curves
12
posses a "shoulder" followed by a logarithmic decline in survival. The shoulder is indicative of
sub-lethal radiation injury. If the surviving fraction of cells is plotted on a logarithmic scale
versus the dose of radiation on a linear scale the slope of the line has two separable components.
The a component of the cell kill, which predominates in the 0-3 Gy range, forms a linear slope
and represents non-repairable radiation damage. The b component has an initial slope that
becomes progressively steeper as the radiation dose increases. The steeper slope of the b curve at
high radiation doses represents the loss of cellular DNA repair mechanisms. Mammalian
radiation survival curves are represented by the following linear quadratic equation:
Loge S = aD + bD2
where S is the fraction of cells surviving the radiation dose, D, and a and b are the constants
(Perez and Brady, 1992).
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Figure 1. Radiation survival curve.
Mammalian cell radiation survival curves have two separable components: a and b. The a cell
kill is caused by non-repairable DNA damage. The b component at less than 10Gy represents
sub-lethal, repairable DNA damage, while at greater than 10Gy represents cell kill due to the
loss of DNA repair mechanisms (Modified from Perez and Brady, 1992).
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5.2 Radiation Induced Cellular Damage.
   Radiation induced cell death is a result of the disruption of two distinct cellular targets: DNA
and the plasma membrane. Through the generation of oxygen free radicals, ionizing radiation
causes physical damage to membrane phospholipids. Damage to the cell membrane may activate
signal transduction cascades important in the apoptosis pathway. One such example is the
generation of ceramide in response to ionizing radiation (Haim vitz-Friedman et al., 1994).  The
sphingomyelinase signal transduction pathway s shown to be activated by ionizing radiation
(Figure 2). In response to radiation, sphi gomyelinase hydrolyzed sphingomyelin, resulting in
the generation of ceramide. This lipid second messenger has been shown to induce apoptosis in
response to ionizing radiation, tumor necrosis factor a (TNF- a) and Fas ligand (Haimovitz-
Friedman et al., 1994; Obeid et al., 1993).
  Another consequence of damage to the plasma membrane by ionizing radiation is the induction
of anti-apoptotic signaling pathways. Membrane lipid peroxidation by ionizing radiation results
in activation of protein ki ase C (PKC) and PKC translocation from the cytosol to the
membrane. Consistent with these findings, is the observation of a biphasic elevation in
diacylglycerol (DAG), a PKC activator, in response to radiation (Nakajima and Yu wa, 1999).
Additionally, PKC activation was shown to block radiation induced sphingomyelin hydrolysis
and apoptosis (Haimovitz-Friedman et al., 1994). Thus, cell fate following exposure to ionizing
radiation, is thought to teeter between apoptosis and survival, as influenced by conflicting pro-
and anti-apoptotic signals from the sp ingomyelin and PKC pathways, respectively (Haimovitz-
Friedman, 1998).
   The best documented target of ionizing radiation is DNA. Ionizing radiation is estimated to
produce 1000 single- and 25-40 double-strand DNA breaks per cell per gray (Olive, 1998).
Ionizing radiation may damage DNA through a direct interaction however, the predominant
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mechanism for damage to DNA is by hydroxyl free radicals (Josephy, 1997). These reactive
oxygen intermediates are generated by the interaction of high-energy radiation with intracellular
water molecules.  The reactive oxygen intermediates cause oxidative damage to nucleotides,
single- and double-strand DNA breaks. Strand breaks in the DNA are caused by the free radical
sequestration of a hydrogen atom at the deoxyribose C4 position, resulting in a loss of the
phosphate linkage and a strand break (Ward, 1988).  It has also been reported that in response to
DNA damage by ionizing radiation, ceramide is produced by the alternative de no o ceramide
synthase pathway (Liao et al., 1999).
Ionizing Radiation
SMase
SM
Plasma
Membrane
Ceramide
Figure 2. Ceramide generation in response to ionizing radiation. Radiation activates
membrane associated sphingomyelinase (SMase) which catalyzes the conversion of
sphingomyelin (SM) to the second messenger, ceramide. Radiation induced damage of
membrane lipids activates PKC. PKC activation blocks sphingomyelin hydrolysis. DNA
damage by radiation activates the de novo ceramide synthase pathway. Ceramide acts as a
signal for apoptosis, while PKC activation counteracts apoptotic signals.
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DNA DamageCeramide
Synthase
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5.3 Radiation Induced Gene Expression.
   In addition to cellular membrane and DNA damage, ionizing radiation induces the expression
of a number of genes and their products. Signal ransduction pathways activated by radiation
such as the stress activated protein kinase (SAPK)/Jun N-terminal kinase (JNK) and mitogen-
activated protein k ase (MAPK) pathways converge in the nucleus, where they activate gene
expression. The immediate-early response genes c-jun, c-fo , myc and c-Ha-ras were induced
within one hour following exposure of transformed lyphoblastoid cells to low doses of radiation
(Prasad et al., 1995). NFkB DNA binding and NFkB mRNA expression were increased in
response to radiation (Brach et al., 1991). Low dose radiation induced transcription of genes
encoding PKC and the EGF receptor while interleukin-1 beta and TNFa were induced by higher
radiation doses (20 Gy) (Woloschack et al., 1990; Peter et al., 1993; Ishihara et al., 1993;
Hallahan et al., 1989). While the particular signal transduction pathways that elicit radiation-
induced gene expression are incompletely understood, it is clear that radiation induces both
nuclear gene expression and cytoplasmic signal tr nsduction.
5.4 Ionizing Radiation Damage and Repair.
   Ionizing radiation induces transient arrests of the cell cycle at G1 and G2 checkpoints. G1
arrest in response to DNA damage is mediated by signals relayed from ATM (ataxia
telengectasia mutated) to p53 (Figure 3). Phosphorylation of p53 by ATM inhibits ubiquitin-
dependent p53 degradation resulting in increased cellular p53 levels. P53 induction of p21 results
in inhibition of cyclins regulating the G1/S transition. G2 arrest is dependent on inhibition of
Cdc2 (cell division cycle protein 2) k ase activity. ATM activated Chk1 and Chk2 (checkpoint
kinase 1 and 2) mediate Cdc2 activity via phosphorylation and subsequent nuclear export of the
Cdc2 phosphatase (Cdc25C). Cdc2 kinase activity is dependent on Cdc25C phosphatase for the
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removal of an inhibitory tyrosine-15 phosphate. In the absence of nuclear CdcC25, Cdc2 remains
phosphorylated, hence inactive, and the G2/M transition is delayed (Dasika et al., 1999). In
addition, a p53-dependent tra scriptional repression of Cdc2 and ycli  B1 may also contribute
to G2 arrest (Bernhard et al., 1995; Passalaris et al., 1999). Recent studies have identified a
function for BRCA1 in the G2 arrest in response to radiation induced DNA damage. BRCA1 was
shown to be an activator of Chk1 and thus essential for G2 arrest in response to DNA damage
(Yarden et al., 2002).
   Pauses in the cell cycle at G1 or G2 checkpoints permit time for repair of damaged DNA
(Cohen-Jonathan et al., 1999). The majority of oxidized lesions in bases and sugars are
effectively repaired by the base excision repair mechanism. This process recognizes and cleaves
the damaged base from the sugar backbone, producing an intermediate single-strand break. The
nucleotide gap in the DNA is filled and then ligated by DNA polymerase and DNA ligase,
respectively (Norburry and Hickson, 2001). It is plausible that if two oxidized base lesions exist
on opposing DNA stands and base excision repair is activated, the formation of two opposing
single-strand break intermediates may result in a double-strand break (Wallace, 1998). In fact,
the number of double-strand breaks induced by irradiation are not sufficient to account for the
lethality of the radiation. It is proposed that additional double-strand breaks are generated during
the repair processing of closely opposed lesions (Ward, 1988; Wallace, 1998).
    Double-strand DNA breaks are the most genotoxic lesions induced by ionizing radiation.
These breaks, which occur as a result of two opposing single-strand breaks in close proximity,
may be repaired by one of three separate pathways. The mechanisms for double-strand break
repair are homologous recombination, single strand annealing and onhomologous end-joining
(Norburry and Hickson, 2001). Among these, nonhomologous end-joining is the primary repair
mechanism for ionizing radiation induced DNA damage in mammalian cells. The process
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involves recruitment of Ku 70, Ku 80, DNA-dependent kinase, XRCC4 and ligase IV proteins to
the site of the double-strand break (Olive, 1998). However, nonhomologous end-joining is not a
perfect repair mechanism; deletions and misrejoined DNA fragments are associated with the
process.
   Damaged DNA which escapes repair challenges the fidelity of DNA replication. Un aired
DNA damage may block DNA replication, thereby inhibiting further cell division. Alternatively,
replication may proceed in the presence of damaged DNA but will amplify errors in the DNA
and eventually cause cell death (Josephy, 1997). In either instance the lethality of the radiation
induced DNA damage is dependent on the cells subsequent attempts at division. Thus faster
proliferating cells are more sensitive to radiation than cells growing more slowly.
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Figure 3. Cell cycle arrest in response to DNA damage.
ATM phosphorylates p53 in response to ionizing radiation (IR) induced DNA damage. P53
induces expression of p21. P21 acts on cyclin-dependent kinase 2 (Cdk2) to inhibit progression
from G1 to S phase. ATM also activates checkpoint proteins 1 and 2 (Chk1 and Chk2). Chk1 and
Chk2 phosphorylate the phosphatase, Cdc25C. Cdc25C is exported out of the nucleus. In the
absence of Cdc25C, cell division cycle protein 2 (Cdc2) is inactive and the transition in cell
cycle from G2 to M phase is arrested (Modified from Dasika et al., 1999).
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6. Radiation Sensitivity
   Different cell and tissue types vary in their sensitivities to radiation. Factors influencing
cellular radiation sensitivity include cell cycle phase, proliferation rate, DNA repair mechanisms,
apoptotic thresholds and tumor oxygenation. Based on the above factors, predictions regarding
tumor cell sensitivity may be made. The late G2 and M phases of the cell cycle, where the DNA
content is 4N, are associated with more radiosensitive cell populations, while the S and G1
phases are relatively radioresistant (Cox, 1994). Proliferating cells are more sensitive to radiation
than non-proliferating cells (Perez and Brady, 1992). Cells with intact DNA repair systems are
less sensitive to radiation than cells lacking components of their DNA repair mechanisms. An
increased threshold for ap ptosis reduces radiation induced apoptotic cell death and yields more
radioresistant cells. Hypoxic tumor cells are r dioresistant compared to more vascularized tumor
cells with adequate oxygenation.
   In 1952, Paterson recognized the differential radiation sensitivities of various tumor types. He
divided all tumors into three groups based on their radiation sensitivities. The most radiosensitive
were embryonic tumors followed secondly by the intermediately sensitive squamous cell and
adenocarcinomas. The least sensitive group of tumor types included soft tissue and bone
sarcomas and melanomas (Perez and Brady, 1992).
   In fact, adenocarcinomas of the breast are highly refractive to radiation induced apoptosis. The
response of breast tumor cells to radiation is growth arrest and reduced clo ogenic survival
(Gewirtz, 2000). Previous studies have shown that in response to 8 Gy radiati n, MCF-7 breast
tumor cells respond by mitotic arrest and giant cell formation (Str bl et al., 1998).
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7. Radiation Sensitizing Agents
   Radiosensitizers are chemical agents that increase the lethal effects of radiation through
modulation of the biological factors influencing radiation sensitivity. In principal, selective
radiosensitization of tumor cells allows for the effective treatment of tumors with lower doses of
radiation which produce fewer side effects in vivo. In the following section agents designed to
increase the sensitivity of cancer cells to radiation will be discussed.
 7.1 DNA Analogues.
   Under development since the 1960s, DNA-base analogs containing halogen atoms have been
used as radiosensitizers. These analogs mimic cellular thymidine and are incorporated into DNA
during the S-phase of the cell cycle and hence offer specificity toward proliferating cells.
Incorporation of halogenated pyrimidines renders the cellular DNA more prone to radiation
induced damage and impairs DNA double-strand break repair (Robertson JM et al., 1996). The
halogenated pyrimidine, 5-bromodeoxyuridine has an increased susceptibility to free radical
formation at the 5-position of uridine. Combining 5-bromodeoxyuridine with radiation results in
permanent DNA damage (Sh noy and Singh, 1992).
   More recently, nucleotide analogs depending on cellular metabolism for activity have been
developed. Gemcitabine is an analog of cytosine arabinoside that upon hosphorylation forms
the metabolite, difluorodeoxycytidine diphosphate (dFdCDP). dFdCDP  inhibits ribonucleotide
reductase, resulting in depletion of deoxyribonucleoside 5'-triphosphate (dNTP) pools. Exposure
of cells to gemcitabine also results in concomitant cell cycle redistribution to S-phase.
Radiosensitization is thought to occur by the concurrent dNTP pool depletion and S-phase
redistribution. The combination of radiation and gemcitabine has shown clinical activity in head
and neck and pancreatic cancers superior to either modality alone (Lawrence et al., 1999).
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   Five-fluorouracil (5-FU) is a uracil analog that is metabolized to fluor deoxyuridine
monophosphate (FdUMP). This metabolite inhibits the hymidylate synthase enzyme responsible
for the conversion of uridylate to thymidylate. Inhibition of thymidylate synthase results in
depletion of thymidine triphosphate (dTTP) pools, cell cycle arrest and DNA fragmentation. The
mechanism that results in cellular r diosensitization is not known but is thought to involve the
inhibition of thymidylate synthase (Robertson et al., 1996). Fluorodeoxyuridine (FdUrd) and 5-
fluorocytosine (5-FC) are potent radiosensitizers that share the same FdUMP metabolite as 5-FU
and similar mechanisms of action. Preclinical findings have shown radiosensitization of colon
cancer cells by fluoropyrimidines (Khil et al., 1996). Clinical evaluation of fluoropyrimidines in
combination with radiation have led to increased survival in patients with pancreatic and
advanced breast cancers (Kaiser and Ellenberg, 1985; Kosma et al., 1997).
7.2 Hypoxic Cell Targeting Compounds.
   Most solid tumors contain as much as 30% hypoxic cells (Denekamp et al., 1980). The oxygen
deficit in tumor cells offers a major exploitable difference between normal and cancer cells.
Hypoxic tumor cells are relatively radioresistant, because in the absence of oxygen, free radical
induced DNA damage is not effective. Another important group of radiosensitizers is n tro
compounds that replace oxygen in the hypoxic tumor cells. The first of these compounds,
metronidazole and misonidazole, were entered into clinical trials in the 1970s. These drugs did
enhance radiation sensitivity n vivo but with serious central neuropathy as a consequence (Perez
and Brady, 1992). The second generation of these compounds including etan dazole and
pimonidazole were effective but dose limiting toxicity due to peripheral neuropathy and acute
central nervous system toxicity, respectively, were encountered. However, these two compounds
have different-dose limiting toxicities. Lower doses of etanidazole and pimonidazole used in
combination result in maximal radiosensitization with minimal toxicity (Taghian et al., 1991).
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   Perfluorocarbons also exploit tumor cell hypoxia, but through a mechanism different than that
of the nitroimidazoles. The perfluorocarbons are able to absorb and release oxygen in high and
low oxygen level environments, respectively. In hypoxic tumor cells, perfluorocarbons enhance
circulation and oxygen distribution (Perez and Brady, 1992). Clinical use of a mixture of
perfluorocarbons, fluosol, in combination with irradiation improved the overall survival of
patients with advanced head and neck tumors (Lustig et al, 1989).
7.3 Alkylating Agents.
   A relatively new class of radiosensitizers is the bioreductive alkylating agents. These
compounds are preferentially metabolized by mitochondrial reductase enzymes in hypoxic tumor
cells. Enzymatic reduction yields an alkylating agent, which targets and forms adduct with
DNA. Mitomycin-C is an example of this type of compound and has been used clinically in
combination with radiotherapy in atients with cancers of the head and neck (Sartorelli et al.,
1994; Boyer, 1997).
7.4 Miscellaneous Compounds.
   Finally, there are numerous other compounds and approaches used in tumor cell
radiosensitization worthy of mention. Repair mechanisms for radiation-induced DNA damage
are valid targets for radiosensitization. Three-aminobenzamide inhibits the repair enzyme,
poly(ADP ribose) synthetase also known as PARP and increases cellular radiation sensitivity
(Winer et al., 1995).
   Campothecan and its derivatives are topoisomerase I inhibitors. These compounds act as
radiosensitizers but the mechanism for this action is not clear. It is proposed that campoth cin
derivatives induce radiation sensitivity by inhibition of DNA repair (Falk and Smith, 1992).
Alternatively, models predict that radiosensitization involves stabilization of the single-strand
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cleavage complex produced by topoisomerase I which when combined with radiation becomes
lethal (Chen et al., 1999).
   Anthracyclines are potent inhibitors of topoisomerase II with radiosensitizing activity.
Radiosensitization of human tumor cell lines has been achieved using aclacinomycin A and
adriamycin (Bill et al., 1992; Lee et al., 1975).
   Reduction of apoptotic threshold is another mechanism for radiosensitization. The farnesyl
transferase inhibitor (FTI-277) blocks ras signal transduction and induces apoptosis in response
to ionizing radiation (Bernhard et al., 1996).
   Redistribution of the cell cycle from resistant to sensitive phases is another promising approach
to increase radiation sensitivity. Paclitaxel, a microtubule stabilizer, arrests cells in the M phase
of the cell cycle and has been shown to act as a radiosensitizer in a variety of human tumor cells
(Kurdoglu et al., 1999).
   Cellular membranes represent a target for radiation as well as for radiation sensitizers. In early
studies, local anesthetics and phe othiazines were shown to sensitize bacterial cells to radiation.
The observation that local anesthetics such as procaine caused r diosensitization was attributed
to damage of bacterial membranes and subsequent leakage of small molecules and metal ions
involved in DNA repair (Shenoy and Singh, 1992). Phenothiazines selectively sensitize hypoxic
tumor cells. It is postulated that this selectivity is related to the differential Fe2+ and Fe3+ ion
concentrations in normal versus tumor cells (Kale, 1996).
   Compounds designed to inhibit intracellular glutathione pools are potential rad osensitizers.
Glutathione counteracts the effects of ionizing radiation by reducing radiation-induced free
radicals. Compounds such as diethylmaleate and buthionine sulfoximine bind or inhibit synthesis
of glutathione, respecively (Perez and Brady, 1992). Radiosensitization in human breast cancer
cells by buthionine sulfoximine is reported (L hnert et al., 1990).
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   Breast cancer cells expressing the HER-2/neu receptor present a unique molecular target for
radiation sensitizers. Herceptin is a monoclonal antibody designed to recognize and block the
HER-2/neu receptor. P eclinical studies have shown that treatment of HER-2/neu expressing
breast cancer cells with the combination of herceptin and radiation results in enhanced radiation
sensitivity and reduced DNA repair (Pietras et al., 1999). A similar story has emerged for the
ErbB-1 receptor which is expressed in a spectrum of cancers of epithelial cell origin. A
monoclonal antibody recognizing ErbB-1, C225, was shown to increase apoptosis in response to
radiation treatment of squamous carcinoma cells (Huang et al., 1999).
8. Protein Kinase C
8.1 Historical Perspective.
   Protein kinase C (PKC) was initially discovered as a calcium activated enzyme (Inoue et al.,
1977).  Subsequently, the PKC enzyme was found to be activated by diacylglycerol (DAG) in a
calcium- and phospholipid-dependent manner (Takaiet al., 1979; Kishimoto et al., 1980). The
pathway of agonist-induced turnover of ph sphatidylinositol had been elucidated some years
prior to the identification of PKC (Hokin and Hokin, 1958). Upon receptor stimulation by an
agonist, phospholipase C is activated and catalyzes the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2). The discovery of PKC proved to be fundamental in assigning a downstream
cellular consequence to the agonist-induced inositol phospholipid pathway. The pathway was
completed with the finding that the products of phosphatidylinositol hydrolysis, inositol 1,4,5-
trisphosphate (IP3), DAG and IP3 stimulating intracellular calcium release, are responsible for
PKC activation.
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8.2 PKC Protein Structure.
   PKC is an evolutionarily conserved group of serine/threonine kinases. The mammalian PKC
family is composed of at least twelve PKC isoforms, which are distinguished on the basis of
protein homology and cofactor utilization. PKC isoforms are divided into three subfamilies:
classical (a, bI, bII, and l), novel (d, e, h, q, and m) and atypical (z and i/g). Each of these
isoforms is encoded by a unique gene with the exception of bI and bII, which share a common
gene. Classical PKC isoforms possess a calcium binding domain and two cysteine-rich zinc
fingers that are involved in DAG binding. While the novel PKC isoforms contain the DAG
binding sites and two cysteine-rich zinc fingers, they lack the calcium binding domain and differ
from the atypical isoforms, which require neither calcium nor DAG for activation and contain a
single cysteine-rich zinc finger motif (Toker, 1998; Kuo, 1994). Atypical PKC isoforms are
dependent on a unique set of activators including PIP2, phosphatidylinositol 3,4,5-trisphosphate
(PIP3), 3-phosphoinositide-dependent protein kinase-1 (PDK-1) and ceramide (Toker, 1998). The
amino termini of all PKC’s contain a pseudosubstrate sequence, which keeps the enzyme in an
inactive form in the absence of activators. The co-factor, phosphatidyl-L-serine promotes
removal of the pseudosubstrate from the catalytic site on the carboxy terminus of the enzyme and
an active PKC conformation (T ker, 1998). Evidence also suggests that displacement of the
pseudosubstrate and calcium cause a translocation of inactive cytosoli  PKC to the plasma
membrane where it assumes an active conformation (Mosior and McLaughlin, 1991).
   The majority of the PKC isoform protein homology differences reside in their regulatory
domains. Classical PKC isoforms contain three variable regions within their regulatory domain,
while the novel and atypical regulatory domains have two variable regions. The catalytic domain
of all PKC isoforms has only one variable region.  PKC isoforms are comprised of between 586
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and 737 amino acid residues and exhibit molecular weights ranging from 67,200 to 83,492
(Hardie and Hanks, 1995).
8.3 PKC Activation.
   Extracellular signals activate tr nsmembrane receptors that activate PKC via the inositol
phosphate pathway (Figure 4). The spectrum of agonists and receptors that stimulate this
pathway includes hormones, growth factors, neurotransmitters and antigens (Kuo, 1994). G-
protein coupled receptors, tyrosine kinas coupled receptors and receptor tyrosine kinases
stimulate the inositol phosphate pathway.
   The first evidence that p ospholipase C activation was coupled to G-proteins came from
experiments showing that G-proteins activators, such as GTPgS or luminum fluoride, stimulated
phosphoinositide hydrolysis (Uh ng et al.,1985; Rock and Jackowski, 1987). Additional evidence
to support these findings was provided by experiments using pertu si  toxin, a Gi- and Go-protein
inhibitor. Toxin treatment of a variety of cell types was shown to inhibit receptor-activated
phosphoinositide hydrolysis (Kikuchi et al., 1986; Nakamura and Ui, 1985). G-proteins are
divided into families based on their substrates where Gq and Go family members mediate
phospholipase C activation (Alberts et al., 1994). Agonist activation of G-protein coupled
receptors results in dissociation of the G-protein heterotrimeric a, b and g subunit complex into
Ga and Gbg and the exchange of Ga bound GDP for GTP. The GTP bound Ga subunit then
may activate phospholipase C. A number of receptors coupled with Gq-proteins, which stimulate
phospholipase C have been identified and include the alpha1-adrenergic, acetylcholine
angiotensin, metabotropic glutamate, muscarinic, thrombin and vasopressin receptors (Varma
and Deng, 2000; Alberts et al., 1994; Sandberg and Ji, 2001; Bordi and Ugolini , 1999; Brown et
al., 1997; Clauser, 1995).
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   Tyrosine kinase receptors are also capable of stimulating phosphoinositide hydrolysis. Two
independent studies showed that point mutations in either the epidermal growth factor (EGF) or
platelet derived growth factor (PDGF) receptors, producing catalytically inactive receptors,
attenuated phophosinositide signaling in response to stimulation by the respective receptor
ligands (Moolenaar et al., 1988; Escobedo et al., 1988). Immunoprecipitation studies revealed a
physical association between phospholipase C and the EGF and PDGF receptors in response to
receptor ligand stimulation (Margolis et al., 1989; Kumjian et al., 1989). The receptor tyrosine
kinases, which are known to stimulate PKC include the EGF, PDGF and fibroblast growth factor
(FGF) receptors (Noh et al., 1995).
   There are several cell surface receptors, which do not contain tyrosine kinase activity but
associate with non-receptor tyrosine kinas s. These non-receptor tyrosine kinas s, such as
members of the src family, are known to stimulate DAG production. For example, the T-cell
receptor, CD3, reportedly interacts with non-receptor tyrosine kinases, such as fyn or lck. Upon
ligand stimulation of the CD3 receptor, phospholipase C and phosphoinositide hydrolysis are
activated (June et al., 1990). In addition, syc mediates phospholipase C stimulation in response to
a2b1 integrin receptor activation by collagen (Keely and Parise, 1996).
   PLC is not the sole enzyme responsible for DAG generation. Phospholipase D (PLD) catalyzes
the hydrolysis of phosphatidylcholine to yield DAG, but through the generation of a phosphatidic
acid intermediate (Kuo, 1994). Like PLC, PLD activity is mediated by G-protein coupled
receptors, tyrosine kinase receptors and non-receptor tyrosine kinaes (Newton, 1995).
Phospholipase A2 catalyzes the generation of cis unsaturated fatty acids which enhance the
activity of PKC in the presence of DAG. (Nishizuka, 1995).
   In addition, there are other lipid second messengers and exogenous molecules that activate
PKC independently of the previously mentioned DAG generating pathways. The tumor
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promoting phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA), acts as a substitute for
DAG through competition for PKC activator and co-factor binding sites. However, fundamental
differences between DAG and TPA in the activation of PKC exist. DAG but not TPA stimulates
phosphodidylcholine and sphingomyelin degradation providing a possible explanation for
differences observed between these two agents. Sphingo ine generated by sphingomyelin
degradation in response to DAG serves as a negative regulator of PKC (Kolesnick and Clegg,
1988). In addition, prolonged treatment with TPA first activates, then depletes cellular PKC.
Short-term exposure, in the range of minutes, to TPA stimulates PKC activity and induces a
translocation of cytosolic PKC to the plasma membrane. Extended exposure to 200 nM TPA is
shown to abolish PKC enzyme activity by 24 hours as measured by 32Pi incorporation into PKC
substrate (Rodriguez-P na and Rozengurt, 1984). Of course, TPA mediates its effects only on the
classical and novel PKC isoforms, which retain DAG sensitivity.
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Figure 4. PKC activation by inositol phospholipid hydrolysis.
Following agonist induced receptor activation, phospholipase C (PLC) catalyzes the
hydrolysis of phosphatidyl 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). IP3 stimulates Ca
2+ release from the endoplasmic reticulum (ER).
PKC is activated by DAG and Ca2+. Phospholipase D (PLD) and phospholipase A2 (PLA2)
catalyze phosphatidylcholine hydrolysis (Modified from Kuo, 1994).
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8.4 PKC Functions and Substrates.
   PKC functions in a variety of normal cellular activities including proliferation, differentiation,
intercellular interactions, cytoskeletal functions and apoptosis. PKC phosphorylates serine or
threonine amino acid residues within its substrates. There are a plethora of physiological PKC
substrates. In the following section a few of the well documented PKC substrates, their signaling
pathways and cellular consequences will be discussed.
   One mechanism whereby PKC mediates cellular growth and differentiation is through the
mitogen-activated protein kinase (MAPK) pathway.  This signaling pathway has been elucidated
and consists of signals transduced from receptors through a series of cytoplasmic proteins:
PKC/Ras/Raf/MAPK kinase/MAPK.  The pathway results in translocation of MAPK to the
nucleus where it phosphorylates target nuclear proteins such as Elk-1, SAP-1, c-Jun and c-Fos.
   Phosphorylation of the nuclear membrane protein, lamin B occurs in response to the PKC
activator bryostatin 1 (Fields et al., 1988). Lamin B phosphorylation preceeds nuclear lamina
disassembly during mitosis. Further studies have shown that PKC activation by phorbol esters
results in lamin B phosphorylation (Hornbeck et al., 1988).
   Finally, the myristoylated alanine-rich C-kinase substrate MARCKS, is a specific substrate of
PKC. MARCKS phosphorylation is commonly used to assess PKC activity. The physiological
roles of activated MARCKS include growth factor-dependent mitogenesis and cell motility
(Hartwig et al., 1992). There are numerous other potential PKC substrates including receptors
(EGF receptor, acetycholine receptor, ransferrin receptor and insulin receptor), nerve cell
proteins (neurogranin and euromodulin), metabolic enzymes (glycogen s nthase) and immune
system proteins (lipocortin I and lipocortin II) (Hardie and Hanks, 1995).
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8.5 PKC Tissue Distribution.
   PKC is widely distributed in mammalian tissues. Some isoforms are expressed ubiquitously
while the expression of other isoforms is restricted to specific tissues. For example, PKC g
expression is restricted to the central nervous system (CNS). The CNS, especially the brain is the
most abundant source of PKC both in the quantity of the protein produced and in the number of
isoforms present (Kuo, 1994). However, several of the 12 documented PKC isoforms are
expressed ubiquitously, including PKC a, bI, bII, d, e and z (Liu and Heckman, 1998).
   The PKC isoform profile determined in the human mammary epithelial cell line, MCF-7,
includes PKC a, d, e, h, g, i, m and z isoforms. MDA-MB-231 human mammary epithelial cell
lines express a PKC isoform profile very similar to MCF-7 cells with the exception that PKC a
is highly expressed in MDA-MB-231 cells and weakly expressed in MCF-7 cells (Morse-Gaudio
et al., 1998; Ways et al., 1995). The PKC isoform expression in tumors may represent a
deviation from the particular PKC isoforms and their levels of expression found in normal
tissues.
8.6 PKC in Cancer.
   PKC participates in abnormal growth processes such as carcinogenesis, tumor progression, and
inflammation (Goekjian and Jirousek, 1999; Weinstein, 1990). As the primary intracellular
receptor for the tumor promoting phorbol esters, PKC plays a role in stimulating early events in
tumor formation. Proliferative signals converging on MAPK from G-protein coupled receptors
and the receptor tyrosine ki ases for epidermal- and platelet-derived growth factors are
transduced through PKC (van Biesen et al., 1995) and could participate in tumor promotion. In
addition, a role for PKC in the later stages of tumor development is suggested by the observation
that the metastatic capacity of tumor cells and PKC activity are positively correlated (Carey et
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al., 1999). Overexpression of the PKC a isoform in MCF-7 cells resulted in increased
extracellular matrix attachments to lymph node and bone marrow receptor ligands and facilitated
metastatic growth (Carey et al., 1999). Activation of PKC by 12-O-tetradecanoylphorbol-13-
acetate (TPA) has been shown to increase extr c llular matrix attachments to capillary
endothelial cells and enhance metastatic growth, while reduction of these attachments and
decreased metastatic activity have been observed in response to PKC inhibition (Herbert, 1993).
   In breast cancer, overexpression and increased activity of PKC compared with normal
mammary tissue have been observed (O’Brian et al.,1989; Gordge et al., 1996). Furthermore,
there is a correlation between elevated PKC protein levels and aggressive breast cancer
phenotypes, such as those that lack estrogen receptors (ER) and exhibit multidrug resistance
(MDR) (Borner et al., 1987; Lee et al., 1992).
8.7 PKC in Response to Radiation.
   PKC gene and protein expression are induced in response to g-radiation (Kim et al., 1992). A
dose dependent elevation in PKC mRNA levels was observed within one hour after ionizing
radiation treatment (Woloschak et al., 1990). PKC activation opposes the pro-apoptotic effects of
ceramide generation by sphingomyelin hydrolysis in response to radiation (Haimovitz-Friedman
et al., 1994). Inhibition of PKC has been shown to increase the sensitivity of human squamous
cancer (Hallahan et al., 1992), mouse embryo fibroblast tumor (Rocha et al., 2000), and human
glioblastoma cell lines (Begemann et al., 1998) to radiation treatment. The specific role of PKC
in radiation response and the individual isoforms involved are not well defined however, the use
of PKC inhibitors, taurosporine, sangivamycin and H7 provided evidence that PKC activation
was radioprotective (Begemann et al., 1998; Hallahan et al., 1992; Zhang et al., 1993). The role
of individual PKC isoforms in the radiation response is not known.
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8.8 Isoform Specific PKC Functions.
   Relatively little is known about cell type specific functions of the individual isoforms in
mammary epithelium. The consequences of PKC overexpression or inhibition in one cell type
may be very different from that in other cell types. For example, overexpression of PKC d in rat
mammary adenocarcinoma cells stimulated anchorage independent growth (Kileyet al., 1999a),
but inhibited growth of cells of ovarian origin (CHO) as well as of mouse NIH3T3 cell
fibroblasts (Watanabe et al., 1992; Mischak et al., 1993). Furthermore, ove xpression of PKC a
stimulated MCF-7 breast tumor and C6 glioma cell growth (Ways et al.,1995; Baltuch et al.,
1995), but overexpression of this same PKC isoform inhibited growth of bovine aortic
endothelial cells and rat embryonic smooth muscle cells (Rosales et al., 1998; Wang et al., 1997).
Thus, generalizations about the role of particular PKC isoforms without regard to cell context
may not be valid. The cellular origins and the PKC isoform profiles are both important
considerations in assigning cell type specific functional roles of PKC. In the following sections
the cell-type specific functions of PKC a, d and z with an emphasis on mammary cell specific
functions will be addressed.
8.9 PKC Alpha (a).
   The Ca2+-dependent PKC a isoform has been shown to be involved with the acquisition of
multi-drug resistant and estrogen receptor (ER) negative breast cancer cell phenotypes. MCF-7
breast cancer cells transfected with PKC a displayed cross-resistance to the anti-cancer drugs
doxorubicin and vinblastine (Yu et al., 1991). The latter finding of a correlation between PKC a
and ER status is evidenced by stable expression of PKC a in MCF-7 cells.  MCF-7 cells
overexpressing PKC a elicited increased proliferation rates and a reduction of ER expression and
estrogen mediated gene expression. MCF-7-PKC-a cells also proliferated in suspension while
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parental MCF-7 cells retained anchorage-dependence for growth (Ways et al., 1995). In response
to PKC a overexpression PKC b protein levels were increased while PKC h levels were reduced
relative to parental MCF-7 cells. These findings suggest that PKC a overexpression correlates
with a more aggressive breast cancer phenotype. However, it is not clear if this is a direct effect
of PKC a overexpression or a consequence of alterations in other PKC is forms.
   A possible explanation for the acquisition of anchorage-independent growth by MCF-7-PKC-a
cells is provided by subsequent studies examining integrin receptor expression. Integrin receptors
mediate xtracellular matrix attachments and are composed of heterodimerized a and b subunits.
The MCF-7-PKC-a cells displayed increased cell surface expression of avb3 a d reduced avb5
intergrins in contrast to parental MCF-7 cells. The altered expression of these av-integrins in
MCF-7-PKC-a cells correlated with an enhanced ability to adhere to vitronectin and osteopontin
containing substrates. Vitronectin and osteopontin are integrin receptor ligands present in the
lymph nodes and bone marrow, respectively. Enhanced attachment of MCF-7-PKC-a cells to
vitronectin and osteopontin indicates an in vivo potential for metastasis to lymph nodes and bone
marrow, the two most common sites of breast cancer metastases (Carey et al., 1999). These
findings suggest that PKC a may be involved in breast cancer metastasis.
8.10 PKC Delta (d).
   PKC d is a novel PKC isoform. This Ca2+-independent isoform has been proposed to both
regulate and serve as a substrate for c spases (Basu and Akkaraju,1999). A possible mechanism
for inhibition of growth by PKC d is through its reported function as a caspase-3 substrate during
apoptosis. Specifically, PKC d is activated by caspase-3 during apoptosis in leukemia cells
resulting in phosphorylation of lamin B (Cross et al., 2000), an event known to precede nuclear
lamina disassembly during apoptosis. In response to TPA treatment, relocalization of
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cytoplasmic PKC d to the mitochondria of MCF-7 cells, preceding cytochrome c release has
been observed (Majumder et al., 2000). These findings support a pro-apoptotic role for PKC d.
   In contrast, growth-promoting activities of PKC d have also been observed in mammary tumor
cells. PKC d involvement in cytoskeleton-dependent processes is evident in MTLn3 mammary
tumor cells. Expression of the inhibitory PKC d regulatory domain (RD d) inhibited growth in
soft agar, cell motility and attachment (Kiley et al.,1999a). The invasive potential of MTLn3
cells was examined by migration of cells through an extracellular matrix coated filter toward
FBS-supplemented growth medium. RD d expression inhibited invasion measured by this assay.
In animal studies, rats were injected with the MTLn3 tumor cells expressing the inducible RD d
construct and 25 days later metastases to the lung were assessed. The number of metastases to
the lung from primary MTLn3 tumors with induced RD d expresssion was significantly reduced
(Kiley et al., 1999b).  Furthermore, in highly metastatic mammary tumor cells derived from lung
metastases, PKC d and z protein and mRNA are significantly increased relative to the less
metastatic primary tumor cells (Kiley et al., 1999a; Kiley et al., 1996). PKC d may positively
influence the progression of mammary tumor cells toward metastasis.
   Ornithine decarboxylase (ODC) is an enzyme essential to cell proliferation. ODC is capable of
inducing cell transformation when overexpressed and is frequently highly expressed in tumor
cells. Dominant negative PKC d expression in murine papilloma cells attenuates induction of
ODC in response to oxidative damage (Otieno and Kensler, 2000). Thus, PKC d might act to
promote cell growth by facilitating the expression of ODC.
8.11 PKC Zeta (z).
 The Ras/Raf signal transduction pathway has provided a link between PKC and the activation of
MAPK. The atypical PKC isoform, z, has been coupled with Raf-1 by the 14-3-3 adapter protein
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family, establishing a Ras independent mechanism for MAPK activation by PKC z in COS cells
(van Der Hoeven et al., 2000). Consistent with PKC z functioning upstream of MAPK, PKC z
dominant negatives impaired MAPK signaling (Berra et al., 1995). Taken together, these
findings support the idea that PKC z, in response to growth factors, leads to MAPK activation
and this may induce cell proliferation.
   Nuclear factor kB (NFkB) is a pro-survival factor and counteracts apoptosis induction by
ionizing radiation (Wang et al., 1996). NFkB activity is dependent on phosphorylation of IkB
kinase (IKK) and the subsequent release of NFkB from the NFkB-IkB complex. PKC z has been
reported to play a critical role in NFkB activation, through phosphorylation of IKK (Lallena et
al., 1999).
   Ceramide participates in a number of intracellular growth inhibitory processes such as
apoptosis, cell cycle arrest and differentiation. A recent study provided evidence that in response
to low concentrations (0.6 mM) of ceramide, PKC z activity, measured by PKC z
autophosphorylation, is increased. Conversely, high concentrations (>2.5 mM) of ceramide
inhibited PKC z activity and induced death in PC12 rat adrenal gland tumor cells.
Overexpression of PKC z rescued cells from ceramide-induced mortality. Treatment of cells
with low concentrations of ceramide correlated with increases in NFkB and Jun N-terminal
kinase (JNK) activities. These studies suggest that cell death in response to low concentrations of
ceramide is counterbalanced by the activation of PKC z, NFkB and JNK (Wang et al., 1999).
Taken together all of the above evidence supports a pro-survival function of PKC z.
   As previously mentioned, PKC z protein and mRNA are elevated in cells derived from lung
metastases in contrast to cells derived from a local primary mammary tumor (Kiley et al.,
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1999a). Apart from this finding, there are no further reports available concerning a role for PKC
z in cells of mammary origin.
8.12 PKC Inhibitors.
   Since the discovery of PKC, efforts have been made to identify inhibitors. To date there are a
large number of identified inhibitors. The targets of PKC enzyme activity inhibitors include the
DAG, lipid cofactor, ATP and substrate binding sites within the enzyme.
   Isoquinolinesulfonamides, like H7, inhibit PKC through competition with the ATP binding.
Because the mechanism of action for isoquinolinesulfonamides is through the ATP binding site,
which is a highly conserved region in all PKC isoforms, they do not offer isoform specificity.
These compounds effectively inhibit PKC activity in the range of 1-10 mM concentrations.
However, within this concentration range cyclic-GMP- and cyclic-AMP-dependent kinases are
inhibited as well (Kuo, 1994).
   Another group of PKC antagonists are those that compete with endogenous substrates for
binding to the PKC substrate binding domain. Chelerythine chloride, a benzophenanthridine
alkaloid, is a potent and selective inhibitor of PKC. Fifty-percent maximal PKC inhibition is
accomplished by a concentration of approximately 1 mM (H rbert et al., 1990).
    The vast majority of PKC enzyme inhibitors are not selective for individual PKC isoforms.
However, there are a few new classes of inhibitors, which offer some degree of PKC isofo m
specificity. Rottlerin selectively inhibits the PKC d isoform (IC50 3-6 mM) by interacting with the
ATP binding site but also inhibits calmodulin kinase III (IC50=5.3 mM) (Way et al., 2000).
   Other groups of recently developed potent inhibitors, such as the taurosporine-derived
indolocarbazoles and bisindolylmaleimides, offer specificity toward a subset of PKC isof rms.
For example the indocarbazoles allow selective inhibition of the classical PKC isoforms (IC50
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0.02-0.03 mM), while members of the bisindolylmaleimide group inhibit classical PKC isofoms
and PKC d and z at nanomolar concentrations (Way et al., 2000).
  Increasingly apparent is the lack of enzyme activity inhibitors, which offer selective inhibition
of single PKC isoforms. DNA technology however, has provided a means to circumvent this
problem through the use of PKC mRNA inhibitors. Oligonucleotides that target RNA are highly
specific PKC isoform antagonists, and may be easier and less expensive to synthesize than
traditional small molecule inhibitors targeted to the enzyme. In the following section antise se
oligonucleotide inhibitors will be discussed.
 9. Antisense Oligonucleotides
   Antisense oligonucleotides are synthetic single-strand DNA (or RNA) molecules composed of
18 to 21 nucleotides, designed to selectively bind, through Watson-Crick base pairing, and
inhibit a specific gene product. Oligonucleotides can inhibit mRNA translation by a number of
different mechanisms including physical blocking of translation or activation of enzymes that
cleave the mRNA species. In their native form, oligonucleotides consist of a phosphodiester
backbone and are rapidly degraded by cellular nucleases. Chemical modification of the
phosphodiester backbone has provided resistance to nuclease degradation. The fundamental
chemical modifications as well as a few of the putative mechanisms of antisense
oligonucleotides will be addressed.
9.1. Chemistry and Mechanism of Action.
   In the first generation of antisense oligonucleotides, non-bridging oxygen atoms in the
phosphate backbone were replaced with sulfur to improve nuclease stability. The
phosphorthioate oligonucleotides are by far the most extensively studied although further
modified second generation oligonucleotides are available. Second generation oligonucleotides
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contain modifications at the 2’-position of the carbohydrate moiety and mixed
phosphorothioate/phosphodiester backbones.
   Theoretically, there are numerous mechanisms whereby the interactions of oligonucleotides
with mRNA result in target mRNA depletion. The first and most simple mechanism involves
physical blocking of translation or nascent mRNA processing. The majority of olig nucleotides
have been designed to bind the translation start codon nd arrest translation. However, the
binding efficiency of these oligonucleotides is affected by 5’-capping of mRNA especially in
mRNA species with lengthy 5’-untranslated sequences. As an alternative to this approach,
oligonucleotides that bind to splicing junctions have been developed. These oligonucleotides
block the splicesome protein complexes necessary for splicing and mRNA maturation and cause
the accumulation of splicing intermediates and a reduction of mature mRNA species.
   The stability of mRNA is influenced by a number of structural features such as the 5’-methyl
cap and the 3’-polyadenylation sequence. Oligonucleotides that interfere with these stabilizing
features may promote mRNA degradation or inhibit translocation out of the nucleus. For
example, oligonucleotides that bind near the 5’-cap site have been shown to be active. The exact
mechanism for their activity has not been determined though.
   A final strategy in the design of olig nucleotides has taken advantage of the endogenous
RNase H enzyme. RNase H is a ubiquitous enzyme that recognizes RNA-DNA duplexes and
catalyzes degradation of the RNA from the duplex. Hybridization of oligonucle tide DNA with
target mRNA produces a sufficient substrate for RNase H. The efficiency of this mechanism is
greatly affected by oligonucleotide backbone modifications. For instance, methlyphosphonate
modified oligonucleotides do not serve as RN e H substrates, while phosphorothioate
oligonucleotides form excellent substrates for RNa e H. Oligonucleotides designed to activate
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RNase H have been the most valuable clinically (For review on antis nse ligonucleotides:
Nielson, 1999; Akhtar and Agrawal, 1997; Lebedeva and Stein, 2001).
9.2 Non-sequence Specific Effects.
   Chemical modification of the native phosphodiester oligonucleotide backbone is somewhat of
a tradeoff: it improves stability but produces non-sequence specific effects. This is especially
true for phosphorothioate oligonucleotides. Reports cite that phosphorothioate oligonucleotides
non-specifically bind several cellular proteins including growth factors and growth factor
receptors producing growth inhibitory effects (Lebedeva and Stein, 2001). For example,
phosphosphorothioate ligonucleotides have been d mostrated to interact with the EGF receptor
and perturb receptor-ligand activation (Rockwell et al, 1997). Additional studies found that
phosphorothioate oligonucleotides bind and displace fibroblast growth factor from the FGF
receptor (Fennewald and Rando, 1995). It should be noted that in both of these independent
studies, binding of the oligonucleotides to cellular proteins occurred at fairly high
oligonucleotide concentrations (2.0 and 0.6 mM, respectively). These findings illustrate the
importance of using appropriate controls in all experimental designs employing a tis nse
oligonucleotides.
9.3 Delivery.
   There are a wide variety of techniques available for the delivery of antisense olig nucleotides
in vitro. Oligonucleotide delivery systems include liposomes, cationic lipids, peptides, starburst
polyamidoamine (PAMAM) dendrimers, electroporation, conjugation with cholesterol,
polycations and conjugation to cell surface ligands. Among these different approaches, cationic
lipids are the most commonly used delivery system for adherent cell types. Typically in in vivo
experiments, oligonucleotides are administered systemically by intravenous injection. Their
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distribution is highly influenced by circulation with highest concentrations of oligonucleotides
present in organs such as the kidney, liver, bone marrow and spleen.
9.4 Clinical Applications.
   Antisense oligonucleotides have been extensively developed for use as therapeutic agents.
Clinical trials employing a tisense have been completed or are underway for the treatments of
cancer, Crohn’s disease and the HIV associated CMV retinitis. In terms of anti-cancer
therapeutics, the targeted gene products in clinical trials include bcl-2, PKC a, ras and raf
kinase. Phase I/II clinical trials utilizing the combination of bcl-2 a tisense and chemotherapy
are underway for the treatment of patients with lymphoma and malignant melanoma. These trials
are expected to be expanded to patients with lung, prostate, renal and breast cancers (Gautshci et
al., 2001).
   PKC a has also shown promise clinically as an anti-cancer therapeutic target. Inhibition of
PKC a by ISIS 3521 antisense oligonucleotide has shown anti-tumor activity in phase I and II
clinical trials in solid tumors (Nemunaitis et al.,1999). ISIS 3521 is now undergoing phase III
clinical trials and is pending approval by the U.S. Food and Drug Administration for the
treatment of non-small cell lung cancer.
   Aside from cancer therapy, the only thus far F.D.A. approved antisense oligonucleotide is
fomivirsen also known as Vitravene (NovartisTM). Fomivirsen is a phosphorothioate
oligonucleotide designed to inhibit replication of the human cytomeg lovirus responsible for
CMV retinitis in AIDS patients. Administration of this oligonucletide is through direct injection
into the affected eye(s). Fomivirsen has been successful in the treatment of previously resistant
CMV retinitis.
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10. Research Objectives
1.   The first goal of this project was to test the following hypothesis:
Inhibition of individual PKC isoforms attenuates the survival of human breast tumor cells
exposed to ionizing radiation treatment. Antisense oligonucleotide PKC inhibitors delivered to
MCF-7 and MDA-MB-231 human mammary tumor cell lines were used to test this hypothesis.
The effect of the PKC antisense oligonucleotides in the absence of radiation treatment was also
tested.
2. A second goal in this project was to examine the effects of the PKC oligonucleotides on
normal mammary epithelial cells.
3. The comet assay was used to test the hypothesis that PKC d and PKC z oligonucleotides
produce DNA damage and enhance radiation induced DNA damage.
4. The final goal of this project was to confirm the PKC oligonucleotide results (goal #1) by
using PKC d and PKC z dominant negative plasmid constructs. The effect of PKC dominant
negative plasmid expression on cell survival was tested.
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II. MATERIALS AND METHODS
1. Materials
1.1 Cells.
MCF-7 cells were provided by Dr. Marc Lippman (Department of Medicine, University of
Michigan). MDA-MB-231 cells were provided by Dr. Mike Miller (Department of Biochemistry
and Molecular Pharmacology, West Virginia University). MCF10A cells were purchased from
American Type Culture Collection (Ma assas, VA). T47-D and MCF-7 cells transformed with
H-ras oncogene were provided by Dr. Michael Moore (Department of Biochemistry, Marshall
University) and Dr. Robert Dickson (Lombardi Cancer Center, Georgetown University),
respectively.
1.2 Antisense Oligonucleotides.
PKC a, d, e, h or z methoxy-ethoxy modified antisense oligonucleotides (ISIS #9606 or
#119406, #13513, #13518, #17000, #13516) and the respective nucleotide scrambled versions of
the oligonucleotides (ISIS #13009, #13514, #13517, #13520,  #128585) were obtained through a
collaboration with Dr. Rob McKay (Isis Pharmaceuticals, Carlsbad, CA). Concentrated
oligonucleotide solutions (1 mM) were diluted in PBS to yield 100 mM working solutions.
Oligonucleotide solutions were stored at -20°C.  PKC oligonucletides are presented in Table 3.
1.3 Drugs.
Rottlerin was purchased from Sigma Chemical Company (St. Louis, MO). Concentrated stock
solutions (6 mM) were made by dissolving rottlerin in dimethyl sulfoxide (DMSO). Working
solutions were prepared by diluting the stocks to 0.2 mM in water. Stock solution was stored at
4°C for 1 month; working solutions were freshly prepared for each experiment.
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1.4 Plasmids.
PKC a, d and z dominant negative plasmid constructs were generously provided by Dr. Bernard
Weinstein (Herbert Irving Comprehensive Cancer Center, Columbia University).
1.5 Antibodies and Purified Proteins.
PKC a, d or e mouse monoclonal antibodies recognizing amino acids 270-427, 114-289 or 1-
175, respectively were purchased from BD Transduction Laboratories (San Diego, CA)
(#P16520, #P36520, #P14820). PKC z goat polyclonal Ab, PKC h rabbit polyclonal Ab, each
recognizing carboxy terminal peptides and bcl-2 mouse monoclonal Ab (SC #216-G, #215,
#509) were purchased from Santa Cruz (Santa Cruz, CA). The horse radish peroxidase-
conjugated anti-mouse IgG (SC #2005), anti-rabbit (SC #2004) and anti-goat (SC #2020)
secondary antibodies were also purchased from Santa Cruz. Purified PKC a, d, e, h and z
proteins (#539674, #539673) were obtained from Calbiochem (San Diego, CA) and used as
standards for western blotting. PKC antibodies are presented in Table 4.
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    Table 3. PKC oligonucleotides
     PKC Isoform      Antisense ISIS#    Scrambled ISIS#
Alpha 9606, 119406 13009
Delta 13513 13514
Epsilon 13518 13517
Eta 17000 13520
Zeta 13516 128585
    Table 4. PKC antibodies
     PKC Isoform      Type                            Recognition Site
Alpha Mouse monoclonalAmino acids 270-427 (hinge and ATP binding domain)
Delta Mouse monoclonalAmino acids 114-289 (cysteine rich repeat domain)
Epsilon Mouse monoclonalAmino acids 1-175
Eta Rabbit polyclonal Carboxy terminus
Zeta Goat polyclonal Carboxy terminus
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2. Methods
2.1 Cell Culture.
MCF-7 (passage #39-50), MDA-MB-231, T47-D and MCF-7ras human mammary tumor cells
were maintained in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker, Walkersville,
MD) supplemented with 10% FBS (Summit Biotechnology, Fort Collins, CO) and 0.04mg/ml
gentamicin in a 7.5% CO2, 37°C, humidified incubator. Cells were passaged weekly at 1:5
(MCF-7 and T47-D) or 1:10 ratios (MDA-MB-231 and MCF-7ras). MCF10A immortalized
human mammary epithelial cells (passage #1-20) were maintained in Mammary Epithelial Cell
Growth Medium (MEGM) (Bio Whittaker) and passaged weekly at a 1:4 ratio.
2.2 Clonogenic Survival.
MCF-7 cells were plated at 1x104 cells/100 mm2 dish in 10 ml DMEM/10% FBS and maintained
for seven days in a 7.5% CO2, 37°C, humidified incubator. To visualize colonies, dishes were
stained with 3 ml of 0.5% crystal violet, 5% formalin, 50% ethanol, 0.85% NaCl for 3 minutes,
then rinsed with tap water. Colonies were scored using a Nikon Eclipse TS100 microscope
(Nikon, Japan) at 100X magnification with ³10 cells =1 colony. For certain experiments, cells
were treated with 1.5-9 mM rottlerin (Sigma, St. Louis, MO) dissolved in DMSO with a final
concentration of 0.1%-0.15% DMSO in the cell culture medium.
2.3 Antisense Oligonucleotides.
MCF-7 (2.2x105), MDA-MB-231 (1.1x105) or MCF10A (1.5x105) cells/35 mm2 dish were
treated for 4-5 hours with 100-200 nM PKC a, d, e, h or z methoxy-ethoxy modified antisense
oligonucleotide, the respective nucleotide scrambled version of the oligonucl otide or the sense
version of the PKC a oligonucleotide in 3 ml Lipofectin (Invitrogen, Carlsbad, CA) transfection
reagent/1 mL Opti-Mem I reduced serum medium (Invitrogen). Transfection mixture was
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prepared by incubating Lipofectin and Opti-Mem at room temperature for 45 minutes.
Oligonucleotides were added to 100 ml of Opti-Mem followed by addition of 100 ml of
Lipofectin:Opti-Mem mixture and 15 minutes incubation. Eight hundred ml of Opti-Mem were
added to the Lipofectin:Opti-Mem:oligonucleotide mixture and the mixture was overlaid on cells
in 35 mm2 dishes washed one time with 1 ml of Opti-Mem. Transfection was stopped after 4-5
hours by medium exchange with DMEM/2% FBS or MEGM (MCF10A).
2.4 Radiation.
Cells were exposed to 0.75-9.5 Gy doses of g-ionizing radiation delivered with a Cesium137
source in a Gammacell 40 (Atomic Energy of Canada Ltd., Ottawa) at 108.7 rads/min or a
Gammacell 1000 (Atomic Energy of Canada Ltd.) at 730.0 rads/min under ambient temperature
and atmospheric conditions. The clonogenic survival curves generated at these two radiation
rates were similar.  After radiation, the culture medium was replaced with DMEM/10%FBS.
2.5 MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) Assay.
Metabolism of MTS was used as index of cell viability. MCF-7, MDA-MB-231 or MCF10A
cells were plated at 1000-2500 (MCF-7) or 250 (MDA-MB-231 and MCF-10A) cells/well in a
96-well plate in 225 ml DMEM/10% FBS or MEGM (MCF-10A). After plating (7 or 5 days,
respectively), fresh growth medium (100 ul DMEM/5% FBS or MEGM + 20 ml Cell Titer 96)
(Promega, Madison, WI)) was added. Conversion of MTS reagent to a colored formazan product
was measured after a 2 hour incubation at 37°C by an increase in absorbance at 490 nm using a
Spectra Max 340pc plate reader (Molecular Devices, Sunnyvale, CA). The MTS assay was linear
under our assay conditions for 3 hours.
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2.6 Western Blotting.
 MCF-7 (7.0x105 cells/100 mm2 dish), MDA-MB-231 (4.5x105 cells/100 mm2 dish) or MCF10A
(1.0x106 cells/100 mm2 dish) were rinsed one time with 37°C phosphate buffered saline (PBS:
0.14 M NaCl, 2.7 mM KCl, 8.1 mM NaHPO47H2O, 1.5 mM KH2PO4). Total cellular proteins
were collected by syringe in 100-150 ml boiling lysis buffer (1% SDS, 10 mMTris, pH 7.4) and
chilled on ice. Proteins were boiled for 5 minutes then centrifuged at 4°C, 14,000rpm in an
Eppendorf centrifuge 5415 C (Brinkmann Instruments Inc., Westbury, NY). Protease inhibitors,
aprotinin, leupeptin and phenylmethyl sulfonyl fluoride at final concentrations of 1 mM, 1 mM
and 100 mM, respectively were added to the supernatant. Protein concentrations were determined
using the BCA assay (Pierce, Rockford, IL). Following the BCA assay, a final concentration of
1mM dithiothreitol was added and protein samples were diluted in 1X sample buffer (0.32 M
Tris-HCl, 10% glycerol, 2% SDS, 0.2% bromphenol b ue, 2.5% 2-mercaptoethanol, pH 6.8) and
then resolved on 7.5% acrylamide gels at 100 V. Proteins were transferred to polyvinylidene
difluoride membranes (Invitrogen) at 25 V for 2 hours. Purified PKC a, d, e, h and z proteins
were used as standards. Membranes were blocked at 4°C, overnight in 3% non-fat dry milk/Tris
buffered saline (TBS: 0.02 M Tris, pH 7.5, 0.5 M NaCl)  + 0.05% Tween20. Membranes were
washed three times, 5 minutes each wash with room temperature western wash solution (0.1%
non-fat dry milk, 0.1% chick ovalbumin, 10% 10X PBS, 1% FBS and 0.2% Tween20).
Membranes were incubated with PKC a, d or e mouse monoclonal antibody, PKC z goat
polyclonal Ab, PKC h rabbit polyclonal Ab or bcl-2 mouse monoclonal Ab for 3 hours 15
minutes. All primary Ab were used at a 1:250 dilution of antibody:western wash solution.
Following primary antibody hybridizations, membranes were washed three times, 5 minutes each
51
wash with western wash solution followed by one 5 minute wash in TBS. Membranes were
hybridized with a 1:1000 dilution of anti-mouse, a 1:8000 dilution of anti-rabbit or a 1:10,000
dilution of anti-goat horse radish peroxidase-conjugated secondary antibody in TBS for 30
minutes. Primary and secondary antibody incubations were performed by placing membranes in
Kapak heat sealable pouches (Kapak Corporation, Minneapolis, MN), adding antibody, heat
sealing the pouch and placing the pouch on a rocker at room temperature for 3 hours and 15
minutes or 30 minutes, respectively. Signals were visualized by incubating the membrane with a
chemiluminescent peroxidase substrate for 7 minutes (Super Signal West Pico
Chemiluminescent Substrate, Pierce, Rockford, IL) and exposing the membrane to film. Signals
were quantitated by FluorChem (Alpha Innotech, San Leandro, CA) spot densitometry using
automatic background subtraction and normalized to a 50kDa or 200kDa protein band on the
Coomassie blue (Pierce) stained acrylamide gel.
2.7 Comet Analysis.
MCF-7 cells (1.0x105 /35 mm2 dish) were harvested two days after plating in 5% FBS and then
counted. Alternatively, MDA-MB-231 cells (1.1x105 cells/35 mm2 dish) were treated with PKC
d or z oligonucleotides and harvested 24-48 hours after treatment. Cells were pellet d in a 15 ml
conical tubes by centrifuging for 5 minutes at 1200 pm, washed with 1 ml ice cold PBS,
centrifuged again and resuspended in ice cold PBS at a concentration of 1x105 cells/ml. Cells
were maintained on ice and treated with 0-5.2 Gy radiation. Alternatively for 1 hour DNA repair
time, cells were irradiated in 35 mm2 dishes and incubated for 30 minutes at 37°C and .5%
CO2. Cells were then harvested (requires 30 minutes) as described above and resuspended in ice
cold PBS for a final concentration of 1x105 cells/ml.   Following irradiation, 50 ml of PBS cell
suspension was mixed with 500 ml of low melting point agarose warmed to 42°C. Seventy-five
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ml of cells in low melting point agarose were spread evenly onto a Comet Slide (#4250-050-03
Trevigen, Gathersburg, MD) and allowed to dry by laying the slide flat in the refrigerator (4°C
and protected from light) for 30 minutes. Slides were then immersed in lysis solution (#4250-
050-01, Trevigen) prechilled for 20 minutes at 4°C and incubated on ice for 45 minutes. Excess
lysis solution was tapped off the slides and slides were transferred to freshly prepared alkali
solution (300 mM NaOH, 1 mM EDTA-pH 8.0) for 45 minutes at room temperature, protected
from light. Slides were transferred to the electrophoresis apparatus and aligned equidistant from
the electrodes. Slides were el ctrophoresed for 30 minutes at 1 Volt/cm (33 V) and 300 mA.
Slides were immersed in 70% ethanol for 5 minutes and then allowed to air dry overnight at
room temperature. Fifty ml of SYBR Green stain [1000X] were added to slides and incubated for
7 minutes, protected from light immediately before data acquisition. Three to five drops of anti-
fade solution were added to SYBR Green stain on slides. The antifade solution was made by
dissolving one 20 mg p-phenylemedaimine dihydrochloride tablet (Sigma #P7288) in 2 ml of
PBS followed by addition of and 18 ml of glycerol. The anti-fade solution was stored in a 3 cc
syringe with a 0.22 mm filter attached at -20°C and protected from light. The comets (nuclei)
were visualized using a Nikon Eclipse TS100 microscope with 63X objective and FITC-filter
cube. Comet images were captured and analyzed using the LAI Automated Comet Assay
Analysis System (Loats Associates, Inc. Westminster, MD). The tail moment [(%DNA)(distance
traveled)] was used for quantitative analysis of DNA damage for 80 comets per treatment per
experiment.
2.8 Charcoal/Dextran Treated Serum.
A 10X dextran coated charcoal solution was prepared (2.5% charcoal, 0.25% dextran, 0.1 M
Tris-pH 7.9) (Sigma D5251 and Fisher #AC404035000). Fetal bovine serum (FBS) was treated
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with 2 units of sulfatase (S8504, Sigma) per ml of serum for 2 hours in 37°C water bath. Seven
ml of the 10X dextran coated charcoal were centrifuged at 3000 rpm in the Sorvall swinging
bucket rotor for the Beckman refrigerated centrifuge for 10 minutes in 50 ml conical tubes. The
supernatant was removed and 35 ml of sulfatase treated FBS was added to the extran charcoal
pellet. This mixture was rocked for 5 hours at 4°C and then centrifuged at 3000 rpm for 10
minutes. Serum was transferred to freshly prepared charcoal pellets, rocked for 5 hours at 4°C
and then centrifuged at 3000 rpm for 10 minutes. Serum was transferred to glass cor x tubes and
centrifuged at 9500 rpm in the Sorvall SS-34 rotor for 30 minutes. Serum was filtered through
0.45 mm then 0.2 mm bottle top filters (#290-3345, 290-3320, Nalg Nunc International,
Rochester, NY). Serum was stored at -20°C. Before use serum was heat inactivated by
incubation in 54°C water bath for 30 minutes.
   For certain experiments, 3,3’,5-triiodo-L thyronine (T3) (T-2877, Sigma) was dissolved in 0.1
M NaOH (70ml 0.01M NaOH/1.0mg T3) and diluted to a 1 mM stock solution with saline
solution (0.154 M NaCl). The T3 stock solution was stored at -20°C. Stock solutions were diluted
in DMEM/10% charcoal/dextran treated FBS to concentrations between 10 nM and 100 mM for
addition to cell growth medium. Cells treated with 5.2 Gy radiation were grown in DMEM/10%
charcoal/dextran treated FBS supplemented with 0.04-4000 nM T3 for 7 days. Cell survival was
estimated by the MTS assay.
2.9 Plasmids.
The HB101 strain of E. coli was transformed with PKC dominant negative mutant pcDNA3
plasmid constructs (Soh et al., 1999) using the Tris-Calcium-Thymidine method as follows.
HB101 was inoculated into 1.5 ml of LB broth and grown overnight with shaking at 120 rpm at
37°C. Forty ml of LB broth in a 250ml flask were innoculated with 0.4 ml of the overnight
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culture and incubated for 2 hours at 37°C with shaking at 120 rpm. Forty ml aliquots of bacterial
culture were placed in 50 ml conical tubes and centrifuged at 2000 rpm for 5 minutes. The
supernatant was removed and bacterial pellets suspended in 10 ml of 4°C Tris-Calcium-
Thymidine buffer (0.01 M Tris-pH 7.5, 0.74% CaCl2, 0.05 mg/ml thymidine).  Bacteria were
collected and transferred to a 30 mlcorex tube and incubated on ice for 15 minutes. Bacteria
were centrifuged at 5000 rpm in Sorvall SS-34 rotor at 4°C for 5 minutes. The supernatant was
removed and the bacteria were gently resuspended in 4 ml of Tris-Calcium-Thymidine buffer
and maintained on ice. Two-hundred ml of competent bacteria were transferred to a 1.5 ml
Eppendorf tube to which 2 ng of plasmid DNA were added. Bacteria and plasmid DNA were
inverted to mix and incubated for 15 minutes on ice. Bacteria were heat shocked for 2 minutes in
a 37°C water bath and then incubated for 10 minutes at room temperature. LB broth (0.5 ml) was
added to the bacteria and bacteria were incubated for 50 minutes in a 37°C incubator. Top agar
was liquified by warming in a microwave and then kept in a 48°C water bath. Three ml of top
agar were aliquoted into glass tubes and placed in the 48°C water bath. Bacteria (0.7 ml) were
added to the center of the top agar using a pasteur pipette and then immediately poured onto LB
agar plates containing ampicillin (0.1 mg/ml). The agar solidified in 10 minutes at room
temperature. Plates were placed upside down in a 37°C incubator and left overnight. On the next
morning, single colonies were picked and streaked onto LB agar plates containing mpi illin.
Plates were incubated at 37°C overnight. Rapid isolation of plasmid DNA was performed by
inoculating 1.5 ml of LB broth containing mpicillin (0.04 mg/ml) with individual colonies
picked from plates and incubating overnight at 37°C with shaking (120 rpm).  The bacteria were
pelleted by centrifuging the overnight culture and were resuspended in freshly prepared TENS
buffer (0.01 M Tris, 1 mM EDTA-pH 8.0, 0.1 M NaOH, 0.5% SDS). The bacteria were placed
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on ice and 150 ml of 3 M sodium acetate, pH 5.2 were added. Bacteria cell membranes and
denatured chromosomal DNA were pelleted and all of the supernatant was added to tubes
containing -20°C 100% ethanol (900ml). Tubes were incubated for 45 minutes in a dry
ice/ethanol slush bath. Plasmid DNA was pelleted by centrifugation for 5 minutes at 14,000 rpm,
4°C. The pellet was washed 2 times with -20°C 70% ethanol and the tubes were inverted to dry.
The pellet was resuspended in 1X TE buffer (0.01 M Tris, 1 mM EDTA, pH 8.0).  PKC inserts
were excised from the plasmid by reacting 5 ul of plasmid DNA with 10 units of Xh  Irestriction
enzyme and 1.5 ml of React 2 Buffer (1X final concentration) (#15231-012, Y92500, Life
Technologies, Inc., Rockville, MD) for 1 hour 45 minutes in a 37°C water bath. Linearized DNA
was electrophoresed in a 0.7% agarose gel at 50 V for 2 hours. Ethidium bromide staining and
visualization by UV light were used to check for appropriate size fragments of linear plasmid
and inserted DNA. Based on these results, bacterial clones containing plasmid co structs with
expected inserts were selected for amplification and purification using the EndoFree Plasmid
Maxi kit (#12362, Qiagen, Valencia, CA) in accordance with the manufacturers protocol.
2.10 Transformation.
MCF-7 cells (1x106/100 mm2 dish) were transformed with 10 mg of the empty vector, 13.7 mg of
PKC d dominant negative or 13.3 mg of PKC z dominant negative (normalized for the neomycin
resistance gene copy number) by the DOTAP transfection reagent (#1811177, Boehringer
Mannheim, Germany). In accordance with the manufacturers protocol, 530 ml of a 1:4 dilution of
DOTAP reagent: 20 mM HEPES (#391333, Calbiochem) buffer (sterile, pH 7.4) were combined
with HEPES buffer containing approximately 0.1 mg/ml of plasmid DNA. The DNA/DOTAP
mixture was incubated at room temperature for 15 minutes and then added directly to culture
medium (9.5 ml DMEM/2% FBS). After 48 hours, medium was exchanged with 10 ml of
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DMEM/5% FBS. On the following day, medium was exchanged with 10 ml DMEM/10% FBS +
400 mg/ml of G418 (#20039, Stratagene, La Jolla, CA). Following 18 days of growth in selection
medium crystal violet staining was performed.
2.11 Statistical Analysis.
Statistically significant differences (P<0.05) were determined using Student's t-test. For multiple
comparisons one-way ANOVA with Tukey's multiple comparison test was used. For interactions
between treatments two-way ANOVA with Bonferroni’s post-test was used.
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III. RESULTS
Chapter 1. Preliminary Results
1.1 Radiation Survival. Clonogenic survival performed in 100 mm2 dishes is a highly sensitive
assay for radiation dose response. Clonogenic survival assays measure the ability of cells to
survive and form colonies at a low plating density. In this case cells were challenged with 0-8.8
Gy doses of g-radiation prior to cloning. Radiation treatments were performed on proliferating
cells released from confluent cultures by subculturing for approximately 24 hours prior to
radiation treatment. MCF-7 cell clonogenic survival was measured using crystal violet staining
and visual colony inspection (Figure 5).  The radiation survival curve shows that radiation doses
in the 0-2 Gy range have a minimal effect on cell survival indicative of radiation-induced DNA
damage repair. Doses greater than 2 Gy produced a dose dependent decline in cell survival.
    Mitochondrial metabolism of the substrate, MTS, was performed with cells growing in 96-
well plates and is another measure of cell survival. Mitochondrial metabolism declined by 65%
in MCF-7 cells seven days after a 5.2 Gy dose of g-radiation as compared to un-irradiated cells.
This radiation response was constant at varied plating densities of 1000 or 2500 cells/well with
control cells reaching approximately 60% and 80% confluency, respectively, after seven days of
growth. It should be noted that MCF-7 cells plated at a higher density (5000 cells/well) showed a
reduced radiation response (32% decrease). This could be explained by reduced growth of
control cells, which exceeded available nutrients during the seven day growth period. While the
MTS assay is not as sensitive as clonogenic survival it offers broad applicability to many cell
types and rapid data acquisition.
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   The MTS assay was also utilized as an index of MDA-MB-231 and MCF-10A cell survival in
subsequent studies. Clonogenic survival is not a suitable endpoint for either of these cell lines
since they do not form discrete colonies. Because MDA-MB-231 and MCF-10A cells have rapid
doubling times in contrast to MCF-7 cells, MDA-MB-231 and MCF-10A cells were permitted
only five days growth prior to end point analysis. Under these conditions all cell types were
allotted appropriate time to complete at least three cell divisions.
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Figure 5. MCF-7 cell clonogenic survival. MCF-7 cells (1x105/35 mm2 dish) 24 h
post-subculture from confluency were treated with 0-8.8 Gy doses of g-radiation.
Following radiation exposure (20 h) cells were harvested and replated at a cloning cell
density of 1x104 cells/100 mm2 dishes. After 7 days of incubation cell survival was
determined by the clonogenic survival assay.  Survival of control cells was set =1. The
efficiency of clonogenic survival in control cells was 9.0%. Data represent the mean
±SD of n=2 independent experiments.
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1.2 PKC Expression in Human Breast Tumor Cells. PKC isoform content varies between
different types of cells. Furthermore, even cells sharing the same origin, such as those derived
from mammary tumors have striking differences in their PKC isoform profiles. To demonstrate
this, western blot analysis of PKC a and PKC z protein in extracts prepared from a panel of
human breast tumor cell lines was performed (Figure 6). Four cell lines commonly used as in
vitro breast tumor cell models were chosen for this experiment: T47-D, MDA-MB-231, MCF-
7ras and MCF-7. A prominent difference in PKC a expression was observed in MDA-MB-231
cells, which express high levels of PKC a relative to the other three cell types. PKC z expression
was high in T47-D, MCF-7 and MCF-7ras, while PKC z expression was minimal in MDA-MB-
231 cells. These experiments do not explain why these differences in PKC protein content occur.
Experiments on extracts prepared from MCF-7 cells at 4 (early G1), 35 (S) and 60 (G2/M) hours
after release from confluency showed no change in PKC d or PKC z protein levels. The doubling
times of these cell types are not the same. Ranked in order of shortest to longest doubling times
are MCF-7ras (24 hours), MDA-MB-231 (27 hours), MCF-10A (38 hours), T47-D (44 hours),
and MCF-7 (60 hours) (Melkoumian, 2001).
T47-D   MDA MCF-7ras  MCF-7 STD
PKC a
PKC z
Figure 6.  PKC protein levels in human breast tumor cell lines. Whole cell extracts
were prepared from T47-D, MDA-MB-231, MCF-7ras and MCF-7 cells (3.0x106/ 0
mm2 dish) 24 h post-subculture from confluency. Proteins (40 mg/lane) were resolved on
7.5% polyacrylamide gels, transferred to filters and probed with antibodies to PKC a and
PKC z. The PKC standards (STD) include purified PKC a (15 ng/lane) and PKC z (40
ng/lane). Data shown are typical of n=2 experiments.
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1.3 MDA-MB-231 Cell Survival in Response to g-radiation and PKC Oligounucleotides. To
identify individual PKC isoforms that positively regulate growth following g-radiation treatment,
antisense oligonucleotides were used as isoform specific PKC inhibitors. This initial screen
utilized liposome delivered oligonucleotides targeted to five PKC isoforms representative of the
classical (a), novel (d, e, h) and atypical (z) PKC subfamilies. The mitochondrial metabolism of
MTS was used as an index of cell survival. Treatment of MDA-MB-231 cells with PKC d or
PKC z oligonucleotide significantly reduced cell survival following radiation insult compared to
treatment with the respective nucleotide scrambled versions of PKC ol gonucleotides (Figure 7).
Liposome treatment alone had no effect on the survival of irradiated MDA-MB-231 cells
however, some non-sequence specific effects of the olig nucleotides were observed. The
nucleotide scrambled version of PKC z reduced survival relative to liposome treatment alone in
irradiated cells. Both the isoform specific and nucleotide scrambled versions of PKC a and
e oligonucleotides reduced cell survival following radiation. Illustrating that oligonucleotide
treatment alone is insufficient to reduce cell survival, neither PKC h nor its nucleotide scrambled
version had an effect on irradiated MDA-MB-231 cell survival.
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Figure 7. MDA-MB-231 cell survival in response to g-radiation +/- PKC antisense
oligonucleotide treatment. MDA-MB-231 cells (1.1x105/35 mm2 dish) 24 h post-
subculture from confluency were treated with 100 nM antisense oligonucleotides plus
liposome that target PKC a, d, e, h and z (gray bars). Controls were treated with
radiation alone (IR), radiation plus li osome (L), or radiation plus lipo ome plus
scrambled nucleotide versions of these oligonucleotides (black bars). Post-tran fection
(24 h), cells were irradiated with 5.6 Gy of g-radiation, harvested and replated in 96-well
plates at a cloning density of 250 cells/well. After 5 days of incubation, cell survival was
estimated using the MTS assay. Data are the mean ±SE of n=4 independent experiments
performed with 5 replicates/treatment. Survival of cells treated with radiation alone was
set =100%. Statistically significant differences between treatment groups receiving PKC
antisense oligonucleotides versus nucleotide scrambled sequence PKC oligonucleotides
are indicated (*P<0.05).
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1.4 MCF-7 Cell Survival in Response to g-radiation and PKC Oligounucleotides. In MCF-7
cells, liposome treatment alone elicited the most significant effect, reducing the survival of
irradiated cells by approximately 50% (Figure 8). The magnitude of the liposome effect
exceeded that of oligonucleotide treatment in affecting survival after g-radia ion treatment.
Nevertheless, PKC d and PKC z oligonucleotides significantly reduced the survival of MCF-7
cells after radiation treatment, thus confirming evidence from MDA-MB-231 cells of the
importance of these two PKC isoforms in the radiation survival of human breast tumor cell lines.
PKC h oligonucleotide treatment increased the survival of irradiated MCF-7 cells relative to its
nucleotide scrambled version, implying a radioprotective effect by the PKC h oligonucleotide.
Consistent with the results in MDA-MB-231 cells (Figure 7), both the isof rm specific and
nucleotide scrambled versions of PKC a and PKC e reduced the survival of g-irradiated MCF-7
cells. The results for PKC a and PKC e in both cell types were inconclusive due to non-sequence
specific effects of the nucleotide scrambled oligounucleotides. Isoform specific actions can only
be distinguished when a nucleotide scrambled version of the oligonucleotide has no effect upon
cell survival.
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Figure 8. MCF-7 cell survival response to g-radiation +/- PKC antisense
oligonucleotide treatment. MCF-7 cells (2.2x105/35 mm2 dish) 24 h post-subculture
from confluency were treated with 200 nM antisense oligonucleotides plus liposome that
target PKC a, d, e, h and z (gray bars). Controls were treated with radiation alone (IR),
radiation plus liposome (L), or radiation plus lipo ome plus scrambled nucleotide
versions of these oligonucleotides (black bars). Post-tran fection (48 h), cells were
irradiated with 5.6 Gy of g-radiation, harvested and replated in 96-well plates at a cloning
density of 2500 cells/well. After 7 days of incubation, cell survival was estimated using
the MTS assay. Data are the mean ±SE of n=3 independent experiments performed with
5 replicates/treatment. Survival of cells treated with radiation alone was set =100%.
Statistically significant differences between treatment groups receiving PKC antisense
oligonucleotides versus nucleotide scrambled sequence PKC oligonucleotides are
indicated (*P<0.05).
66
1.5 Treatment with PKC Oligonucleotides in the Absence of Liposome. MCF-7 cell survival
is significantly impaired by treatment with liposome alone (Figure 8). In an effort to separate the
effects of PKC oligonucleotides from those of liposomes, oligonucleotide treatments were
performed in the absence of a lipid carrier. For these experiments, oligonucl otide concentrations
were increased to 9 mM, a concentration previously shown to produce a phenotype in MCF-7
cells consistent with c-myc depletion by c-myc oligonucleotides in the absence of liposome
(Melkoumian  and Strobl, 2002). Treatment of MCF-7 cells with 9 mM PKC d, PKC z or the
respective scrambled o igonucleotides had no effect on cell survival (Figure 9A). In addition, if
oligonucleotide treatments were followed by exposure to 5.2 Gy radiation, no differences
between PKC and scrambled oligonucleotides were observed, although a reduction in cell
survival was observed in all cells that received any oligonucleotide compared to those treated
with radiation alone. Futhermore, this same experiment was performed in MDA-MB-231 cells
with no effect by the PKC d or PKC z oligonucleotides (Figure 9B). In previous experiments, the
combination of liposome and 100 nM PKC d oligonucleotide produced a significant decrease in
MDA-MB-231 cell survival. We conclude that 9 mM PKC oligonucleotide without a lipid carrier
was ineffective at reproducing the effects on cell survival of iposome delivered PKC d or PKC z
oligonucleotides.  These findings suggest that these PKC oligonucleotides require complexation
with liposomes for effective delivery.
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Figure 9.  PKC oligonucleotide treatment without liposome. (A) MCF-7 cells
(2.2x105/35 mm2 dish) 24 h post-subculture from confluency were treated with 9 mM PKC
d or PKC z antisense oligonucleotides and 48 h later, treated with 5.2 Gy IR, harvested
and replated (2500 cells/well) in 96 well-plates. (B) MDA-MB-231 cells (1.1x105/35 mm2
dish) were treated as in (A), except replated at a density of 250 cells/well 17 h post-
oligonucleotide treatment. MTS activity was measured after 7 and 5 days (A and B,
respectively) as an index of survival. Data are the mean ±SD of 5 replicates/treatment in a
single experiment. Survival of control cells was set =100%.
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1.6 Immunoblot Analysis of PKC Oligonucleotide Treated Cells. To gain insight into the
kinetics of oligonucleotide action on PKC protein levels, western blot analyses of extracts from
MDA-MB-231 cells prepared at various times following PKC a oligonucleotide treatment were
performed. Extracts from MDA-MB-231 cells prepared 5 or 24 hours after treatment with PKC
a oligonucleotide did not show reductions in PKC a protein levels (Figure 10A). Cell extracts
prepared at later time points (48-96 hours) following PKC a oli onucleotide treatment, yielded
marked reductions in PKC a protein levels (Figure 10B). These results indicate that PKC a is 
stable protein. PKC oligonucleotides likely produce rapid reductions in target mRNA levels and
therefore prevent de novo PKC protein synthesis. However, pre-existing PKC protein is not
affected by oligonucleotide action and its reduction is dependent on roteolytic degradation. The
lag between inhibition of de novo PKC synthesis and degradation of pre-existing PKC appears to
be in the range of 48 hours.
   For additional evidence that oligonucleotides inhibit PKC protein levels, PKC e protein levels
were assessed. Whole cell lysates were prepared from MDA-MB-231 cells 52-72 h after PKC e
oligonucleotide treatment. Immunoblot analysis demonstrated reductions in PKC e protein levels
by the isoform specific oligonucleotide compared to controls (Figure 11). Extracts prepared from
PKC e oligonucleotide treated cells yielded dilute protein concentrations and this may account
for the difference in mobility observed within the PKC e signals. The conclusion from these
studies is that PKC oligonucleotides are effective inhibitors of synthesis of PKC isof rms and
require at least 48 hours for optimal PKC isoform protein reduction. These conclusions are
consistent with PKC oligonucleotide studies performed by collaborators at Isis Pharmaceuticals.
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Figure 10. Immunoblot analysis of PKC a antisense oligonucleotide treated cells.
MDA-MB-231 cells (6.0x105/100 mm2 dish) 24 h post-subculture from confluency were
treated with lipofectin alone (L), 100 nM PKC a antisense oligonucleotide (PKC a) or
the nucleotide scrambled version (SCR). Whole cell extracts were prepared from cells 5 h
and 24 h (A) or 48-96 h (B) after treatments. Proteins (20 mg/lane) were resolved on 7.5%
polyacrylamide gels, transferred to filters and probed with PKC a an ibody. The PKC
standard (STD) is 4 ng of purified PKC a protein. The signal density for cells treated
with the nucleotide scrambled version (A) or lipofectin alone (B) was set =100%. Signal
densities were normalized to a 200 kDa protein band on the Coomassie blue-stained
acrylamide gel. Results are from a single experiment.
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Figure 11. Immunoblot analysis of PKC e antisense oligonucleotide treated cells.
MDA-MB-231 cells (5.0x105/ 0 mm2 dish) 24 h post-subculture from confluency were
treated with lipofectin alone (L), 100 nM PKC e antisense oligonucleotide (PKCe), the
nucleotide scrambled version (SCR) or no treatment (C). Whole cell extracts were
prepared from cells 52-72 h after treatments. Proteins (50mg/lane) were resolved on 7.5%
polyacrylamide gels, transferred to filters and probed with PKC e an ibody. The PKC
standard (STD) is 4 ng of purified PKC e protein. Control signal densities were set
=100%. Signal densities were normalized to a 200kDa protein band on the Coomassie
blue-stained acrylamide gel. Results are from a single experiment.
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1.7 Radiation Induced DNA Damage. Radiation produces rapid DNA damage in the form of
single- and double-strand DNA breaks. Alkaline electrophoresis of single cells following
radiation treatment and cell lysis permits the separation of intact nuclear DNA from fragmented
DNA, forming a discernible comet head and tail, respectively (Fairbiarn, 1995). Using the comet
assay, experiments to quantify DNA damage and subsequent damage repair in MCF-7 cells were
performed. For unirradiated control cells, the tail moment which measures the amount of
damaged DNA in the tail and the electrophoretic distance traveled, was near zero (Figure 12).
Following low dose radiation treatment (1.5 Gy), migration of DNA from the head of the comet
was observed and is evidenced by the shift in the distribution frequencies toward higher tail
moment values. In response to 5.2 Gy of radiation, the distribution of comets observed shifted
toward higher values for the tail moment parameter.  Interestingly, if MCF-7 cells were
incubated for one hour at 37°C before lysis, DNA damage induced by 1.5 or 5.2 Gy irradiation
was repaired. In conclusion, these experiments provide evidence that DNA damage and repair
are rapid responses to g-radiation treatment. The comet assay is a quick and sensitive method for
detection and quantification of DNA damage.
74
Figure 12. Radiation induced DNA damage in MCF-7 cells. MCF-7 cells (1x105/35
mm5 dish) 48 h post subculture from confluency were treated with 1.5 or 5.2 Gy g-
radiation or cells were incubated 1 h for repair of DNA damage post-irradiation
(1.5Gy/5.2Gy  + 1h) were analyzed by the comet assay as described in methods. The
number of comets with tail moments in ranges between 0-2, 5-10, 10-20, 20-50, 50-100
and >100 are plotted for each treatment group. Data represent n=3 independent
experiments with 80 comets scored per treatment/experiment. Statistically significant
differences are indicated below (*P<0.05). The images shown are typical of the majority
of comets for the respective treatment groups.
Statistical Analyses (ANOVA)
Comparison                                          P Value
*Control vs. 1.5Gy                                    <0.05
*Control vs. 5.2Gy                                    <0.05
*1.5Gy vs. 5.2Gy                                      <0.05
*1.5Gy vs. 1.5Gy +1h                               <0.05
*5.2Gy vs. 5.2Gy +1h                               <0.05
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1.8 Thyroid Hormone Manipulation In Vitro. Clinical studies have revealed that induction of
hypothyroidism in patients with recurrent gliomas produces prolonged survival (Hercbergs,
2000; 1999). Additional evidence suggests that triiodothyronine (T3) stimulates growth by
mimicking estrogen in estrogen receptor positive breast cancer cell lines (Nogueira a d Brentani,
1996). For these reasons, experiments were conducted to test if T3 depriva ion would impair
breast tumor cell survival in response to g-radiation treatment.  Because selective depletion of
thyroid hormone from serum is not a practical experimental design, fetal bovine serum (FBS)
was charcoal/dextran and sulfatase treated to remove growth factors and hormones. MCF-7 cell
growth in treated serum versus untreated FBS was inhibited in the presence or absence of
radiation treatment (Figure 13). Addition of T3 to charcoal/dextran treated growth medium did
not stimulate MCF-7 cell proliferation in irradiated or unirradiated cells (Figure 14). In
summary, the MCF-7 cells used in these experiments did not display T3 responsiveness.
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Figure 13. MCF-7 cell survival in charcoal/dextran treated FBS. MCF-7 cells
(1.1x105/35 mm2 dish) 24 h post-subculture from confluency were treated with 5.2
Gy g-radiation. Post-irradiation (20 h) cells were harvested and r plated in 96-well
plates at a cloning density of 1500 cells/well. Cells were grown in DMEM/10%
charcoal/dextan treated FBS or untreated FBS for 7 days. Cell survival was estimated
using the MTS assay. Data are the mean ±SD of n=2 independent experiments
performed with 5 replicates/treatment. Survival of cells grown in untreated FBS was
set =100%.
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Figure 14. MCF-7 cell response to T3. MCF-7 cells (1.1x10
5 cells/35 mm2 dish) 24 h
post-subculture from confluency were treated with 5.2 Gy g-radiation. Post-irradiation
(20 h) cells were harvested and replated in 96-well plates at a cloning density of 1500
cells/well. Cells were grown in DMEM/10% charcoal/dextran treated FBS supplemented
with increasing concentrations of 3,3’,5-triiodo-L thyronine (T3) for 7 days. Cell survival
was estimated using the MTS assay. Data are the mean of 5 replicates/treatment ±SD in a
single experiment. Survival of cells grown in DMEM/10% charcoal/dextran treated FBS,
without T3 or radiation was set =100%.
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Chapter 2. PKC d is a Pro-survival Factor in Human Breast Tumor Cell Lines.
2.1 Radiation Survival Curves. Cell survival following exposure to increasing doses of g-
radiation was measured using mitochondrial metabolism of MTS as an end-point. This assay is
rapid, reproducible and suitable for screening purposes. Using the MTS assay, the human
mammary tumor cell lines, MDA-MB-231 and MCF-7, used for these studies showed similar
radiation survival curves (Figure 15). However, at the radiation doses of 3.7 and 6.6 Gy the
survival of MDA-MB-231 cells was significantly greater than that of the MCF-7 cells.
Radiation Dose (Gy)
0 2 4 6 8 10
C
e
ll 
S
u
rv
iv
a
l 
(%
)
0
20
40
60
80
100
120
MCF-7
MDA-MB-231
*
*
80
Figure 15. Radiation survival curves of MDA-MB-231 and MCF-7 cells. MDA-MB-
231 and MCF-7 cells were treated with 0-9.5 Gy doses of g-radiation. Following radiation
exposure (20 h) cells were harvested and replate at cloning cell densities of 250 (MDA-
MB-231) and 1500 (MCF-7) cells/well in 96-well plates. After 5 (MDA-MB-231) or 7
(MCF-7) days of incubation cell survival was determined by MTS assay. Control cell
survival was set =100%. Data represent the mean ±SE of n=3 independent experiments
performed with 5 replicates/treatment. Statistically significant differences between the
two cell lines are indicated (*P <0.05).
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2.2 Differential Expression of PKC Isoforms in MDA-MB-231 and MCF-7 Cells. Individual
PKC isoforms are differentially expressed within human mammary tumor cells. Western blot
analysis of MDA-MB-231 and MCF-7 cell extracts was performed to examine the relative
protein levels of PKC a, PKC d, PKC e, PKC h and PKC z (Figure 16). The major difference in
the PKC expression profile between these two cell lines is the PKC a isoform expression. PKC
a is present at higher levels in the estrogen receptor-negative MDA-MB-231 cells than in
estrogen receptor-positive MCF-7 cells. This finding is supported by previous investigations
concluding a negative correlation between PKC a expression and estrogen receptor status in
mammary tumor cells (Morse-Gaudio et al., 1998; Ways et al., 1995). MDA-MB-231 and MCF-
7 cells also differed in their expression of the PKC h isoform. While MCF-7 cells contain two
species of PKC h, a faster and slower migrating form, PKC h was undetectable in MDA-MB-
231 cells. The correlation between PKC a overexpression and an absence of PKC h protein in
MDA-MB-231 cells is consistent with previous reports where transformation of MCF-7 cells
with PKC a results in reduction of PKC h protein (Ways et al., 1995). These results and
previous findings support the correlation between PKC a overexpression and a less
differentiated breast tumor cell phenotype. The expression of PKC d, PKC e and PKC z were
similar between the two cell lines.
PKC a
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PKC e
PKC h
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Figure 16.  PKC protein levels in MDA-MB-231 and MCF-7 cells. Whole cell extracts
were prepared from MDA-MB-231 (3.5x106/100 mm2 dish) or MCF-7 (2.5x106/ 0 mm2
dish) cells 24 h post-subculture from confluency. Proteins (40 mg/lane- a, e, h, z and 62
mg/lane- d) were resolved on 7.5% polyacrylamide gels, transferred to filters and probed
with antibodies to PKC a, PKC d, PKC e, PKC h and PKC z. The PKC standards (STD)
included purified PKC a (15 ng/lane), PKC d (15 ng/lane), PKC e (5 ng/lane), PKC h (3
ng/lane) and PKC z (40 ng/lane). Data shown are typical of n=2 experiments.
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2.3 PKC d Oligonucleotides Decreased Survival in Human Breast Tumor Cells. PKC gene
and protein expression are induced following ionizing radiation (Woloschak et al., 1990; Kim et
al., 1992). PKC inhibition radiosensitizes human squamous carcinoma, human colon
adenocarcinoma, transformed mouse embryo fibroblasts and human glioblasto a cell lines
(Hallahan et al., 1992; Zaugg et al., 2001; Rocha et al., 2000; Begemann et al., 1998). The goal
of this project was to examine the roles of specific PKC isoforms on cell survival in response to
radiation insult by 5.6 Gy. Oligonucleotides that targeted the novel PKC isoform, PKC d were
introduced into the two human breast tumor cell lines using liposomes. Treatment of MDA-MB-
231 cells with PKC d oligonucleotide decreased cell survival  (P<0.05) in the irradiated cells by
44% compared with cells that were treated with the nucleotide scrambled version of this
oligonucleotide (Figure 17A). Liposome treatment alone or lip some treatment plus the
nucleotide scrambled version of the PKC d oligonucleotide had no effect on MDA-MB-231
survival indicating that the oligonucleotide sequence was critical to the decreased survival.
   In MCF-7 cells (Figure 17B), liposome treatment alone reduced survival of irradiated cells by
approximately 50%, and the magnitude of the liposom effect exceeded that of oligonucleotide
treatment in affecting cell survival after g-r diation. Nevertheless, PKC d oligonucleotides
significantly decreased the survival of MCF-7 cells after radiation treatment, thus providing
confirmatory evidence for the importance of this PKC isoform in the radiation survival of human
breast tumor cell lines. It was concluded that PKC influences breast tumor cell survival
following ionizing radiation in an isoform specific manner and that PKC d oligonucleotide
effects on the survival of irradiated MDA-MB-231 and MCF-7 cells are quite specific.
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Figure 17. Cell survival in response to g-radiation +/- PKC d oligonucleotide
treatment. (A) MDA-MB-231 cells (1.1x105/35 mm2 dish) were treated with 100 nM
PKC d (PKCd) antisense oligonucleotide plus iposome. Controls were treated with
radiation alone (IR), radiation plus li osome (L), or radiation plus lipo ome plus a
scrambled nucleotide version of PKC d oligonucleotide (SCR). Post-transfection (24 h),
cells were irradiated with 5.6 Gy ofg-radiation, harvested and replated in 96-well plates
at a cloning density of 250 cells/well. After 5 days of incubation, cell survival was
estimated using the MTS assay. (B) MCF-7 cells (2.2x105/35 mm2 dish) were treated with
200 nM PKC d antisense oligonucleotide or controls as described in (A). Cells were
irradiated with 5.6 Gy g-radiation 48 h post-transfection, harvested and replated in 96-
well plates at a cloning density of 2500 cells/well. After 7 days of incubation, cell
survival was estimated using the MTS assay. Data are the mean ±SE of n=4 (A) or n=3
(B) independent experiments performed with 5 replicates/treatment. Survival of cells
treated with radiation alone was set =100%. Statistically significant differences between
groups treated with PKC d antisense oligonucleotide versus scrambled version of PKC d
are indicated (*P<0.05).
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Figure 17A. MDA-MB-231
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Figure 17B. MCF-7
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2.4 PKC d Oligonucleotides Specifically Reduced PKC d Protein Levels. To further analyze
the role of PKC d oligonucleotide in breast tumor cell survival post-irradiation, PKC d pr tein
levels in cells treated with ol gonucleotide that targeted PKC d were assessed.  Whole cell
extracts were prepared from MCF-7 and MDA-MB-231 cells either 52 h or 72 h after
transfection with PKC d oligonucleotide. These time points were chosen based preliminary
studies that assessed the kinetics of PKC a antisense oligonucleotide and showed that optimal
protein depletion required at least 48 hours.  No PKC d pr tein was detected in either cell line
after 72 h (Figure 18 and 19). Untreated cells, cells treated with lipofectin alone or the inactive
nucleotide scrambled version of the PKC d oligonucleotide showed constant levels of PKC d at
52 and 72 h. The PKC d oligonucleotide transfection protocol, but not the control conditions
used in the radiation survival experiments, depleted human breast tumor cell lines of PKC d
protein. To test whether the effect of PKC d oligonucleotide was selective for the d isoform of
protein kinase C, protein levels of PKC e and PKC z were assayed in the MCF-7 cell extracts
(Figure 18). There was no effect of the PKC d oligonucleotide on levels of either PKC e or PKC
z. Bcl-2 is an anti-apoptotic protein that is highly expressed in human breast tumor cells (Eissa et
al., 1999). To test whether the effect of PKC d ligonucleotide could be manifested as a decrease
in bcl-2 protein levels immunoblot analysis for bcl-2 was performed. Figure 18 and 19 show that
the levels of bcl-2 protein are constant in MCF-7 and MDA-MB-231 cells treated with the PKC
d oligonucleotide. Furthermore, the quantitated and normalized bcl-2 signal densities showed no
significant differences (n=3, P<0.05) in response to control or PKC d oligonucleotide treatments
in either cell line. The decreased survival of irradiated cells following depletion of PKC d rotein
with PKC d oligonucleotide can not be attributed to a decrease in bcl-2 protein. We conclude that
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reduced cell survival by PKC d oligonucleotide is due to specific depletion of PKC d protein
from human breast tumor cells.
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Figure 18. Immunoblot analysis of PKC d oligonucleotide treated MCF-7 cells.
Whole cell extracts were prepared from MCF-7 cells (7.0x105/100 mm2 dish) 52-72 h
after treatment with lipofectin alone (L), 100 nM PKC d antisense oligonucleotide
(PKCd), the nucleotide scrambled version (SCR) or no treatment (C). Proteins (20
mg/lane) were resolved on 7.5% polyacrylamide gels, transferred to filters and probed
with antibodies to PKC d, PKC e, PKC z and bcl-2. The PKC standards (STD) included
purified PKC d (15 ng/lane), PKC e (5 ng/lane) and PKC z (25 ng/lane). Data in graph
are the mean ±SE of n=3 independent experiments. Control signal density was set
=100%. PKC d signal densities were normalized to a 200 kDa protein band on the
Coomassie blue-stained acrylamide gel. Statistically significant differences between
treatment groups receiving PKC d antisense oligonucleotide versus nucleotide scrambled
sequence of PKC d oligonucleotide are indicated (*P<0.05). Blots are typical of n=3
independent experiments.
PKC d
PKC e
PKC z 
Bcl-2
52h 72h
P
K
C
 dd
 P
ro
te
in
 (
%
 c
o
n
tr
o
l)
0
20
40
60
80
100
120
*
*
C L SCR PKC d C L SCR PKC d
52 h 72 h
C L SCR PKC dSTD C L PKC dSCR
89
90
Figure 19. Immunoblot analysis of PKC d oligonucleotide treated MDA-MB-231
cells. Whole cell extracts were prepared from MDA-MB-231 cells (5.0x105/100 mm2
dish) 52-72 h after treatment with lipofectin alone (L), 100nM PKC d antisense
oligonucleotide (PKCd), a nucleotide scrambled version (SCR) or no treatment (C).
Proteins (20 mg/lane) were resolved on 7.5% polyacrylamide gels, transferred to filters
and probed with antibodies to PKC d and bcl-2. The PKC d standard (STD) is 15 ng of
purified PKC d protein. Data in graph are the mean ±SE of =3 independent experiments.
Control signal density was set =100%. PKC d signal densities were normalized to a 200
kDa protein band on the Coomassie blue-stained acrylamide gel. Statistically significant
differences between treatment groups receiving PKC d a tisense oligonucleotide versus
nucleotide scrambled sequence of PKC d oligonucleotide are indicated (*P<0.05). Blots
are typical of n=3 independent experiments.
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2.5 PKC d Protein Levels Are Elevated in Response to Ionizing Radiation Treatment.
Previous experiments supported the hypothesis that PKC d is  survival factor in breast tumor
cells. To evaluate whether PKC d might augment survival following radiation treatment, PKC d
protein levels post-irradiation were examined. At early (3 h) and late time points (21 h) after
treatment with 5.2 Gy g-radiation, PKC d protein levels were significantly (n=3, P<0.05)
elevated in extracts prepared from irradiated cells compared to non-irradiated controls (Figure
20). In addition, experiments performed in parallel showed no change in PKC z prot in levels
following radiation treatment (Figure 31). These findings support the hypothesis that PKC d also
acts as a survival factor in response to ionizing radiation-induced DNA damage.
Time Post-IR (hours)
3h 21h
No IR  5.2GyIR No IR  5.2GyIR
Figure 20. PKC d protein levels in MCF-7 cells following exposure to ionizing
radiation. Whole cell extracts were prepared from MCF-7 cells 3 h and 21 h after
exposure to 5.2 Gy radiation. Proteins (25 mg/lane) were resolved on 7.5% acrylamide
gels, transferred to filters and probed with an antibody to PKC d. A Coomasie blue-
stained protein is shown as the loading control. Data shown are representative of n=3
independent experiments.  
PKC d
50KD
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2.6 Rottlerin Reduced Cell and Clonogenic Survival. To test the hypothesis that PKC d is a
survival factor in breast tumor cell lines, c onogenic survival assays with MCF-7 cells following
exposure to r ttlerin, a PKC d selective PKC inhibitor were performed. Clonogenic survival
assays are a sensitive measure of drug activity, and the MCF-7 cells were highly responsive to
rottlerin under these conditions.  Clonogenic survival of MCF-7 cells exposed to 3 mM r ttlerin
for seven days, was reduced by 78% compared to control cells exposed to the solvent alone
(Figure 21). The published IC50 value for ottlerin inhibition of purified PKC d is 3-6 mM
(Gschwendt et al., 1994). These results support the hypothesis that PKC d is a survival factor in
breast tumor cells. The effect of ro tlerin on the survival of MCF-7 and MDA-MB-231 cells
following g-radiation was also tested (Figure 22A and B). MCF-7 cells were exposed to either
1.5 or 5.2 Gy of g-radiation. MDA-MB-231 cells were tested only at the 5.2 Gy radiation dose.
After radiation, the cells were harvested and plated into 96-well dishes containing medium with
varying concentrations of rottlerin. MCF-7 cell radiation survival measured by the MTS assay
was reduced by treatment with 3 mM rottlerin. MDA-MB-231 cells were even more sensitive to
3 mM rottlerin in the presence or absence of radiation (Figure 22B) than MCF-7 cells. In either
cell type 3 mM was the minimum concentration of r ttlerin required to produce a statistically
significant decrease in cell survival at each radiation dose with no significant interaction detected
between the radiation and rottlerin treatments.
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Figure 21. Effect of rottlerin on clonogenic survival. MCF-7 cells (1.0x104 /100 mm2
dish) were treated with indicated concentrations of rottlerin. Cells were left undisturbed
for 7 days then plates were stained with crystal violet to visualize colonies. The cloning
efficiency for control cells was 11.0% and this was set =100%. The mean (±SE)
clonogenic survival was determined for n=3 independent experiments. Statistically
significant differences between control and treatment groups are indicated (*P<0.05).
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Figure 22. Effect of rottlerin on cell survival. (A) MCF-7 cells (3.0x105/ 35 mm2 dish)
were treated 1.5 or 5.2 Gy g-radiation (IR), harvested, r plated at a cloning density of
2500 cells/well and treated with indicated concentrations of rottleri . Cells were grown
for 7 days and cell survival was determined by MTS assay. (B) MDA-MB-231 cells
(2.0x105/35 mm2 dish) were treated as in (A) but with 5.2 Gy IR, replated at a cloning
density of 250 cells/well and grown for 5 days. Data are the mean ±SE of n=3
independent experiments performed with 5 replicates/treatment. Survival of control cells
was set =100%. Statistically significant differences between control and rottlerin
treatments are indicated (*P<0.05).
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2.7 The Effects of PKC d Oligonucleotide and Low Dose g-Radiation on Breast Tumor Cell
Survival. Breast cancer radiation therapy is delivered in the range of 1-2 Gy/treatment.  To
determine whether PKC d oligonucleotide would decrease breast tumor cell survival in vitro in
this radiation dose range, cells were exposed to 1.5 Gy radiation 17 h after transfection with
oligonucleotides. Control, non-irradiated cells were treated in parallel with PKC d
oligonucleotide or its nucleotide scrambled version. PKC d ligonucleotide treatment reduced
the survival of MDA-MB-231 treated with a 1.5 Gy dose of radiation (Figure 23A). Consistent
with earlier results (Figure 17A), a 40% decrease in cell survival over five days was observed in
non-irradiated MDA-MB-231 cells treated with the PKC d compared with the nucleotide
scrambled oligonucleotide (Figure 23A). Survival of the MDA-MB-231 cells exposed to the low
dose of g-radiation (1.5 Gy) alone was decreased approximately 20% compared to non-irradiated
controls. Pre-treatment of the cells with the PKC d oligonucleotide caused cell survival to
decrease by approximately 70%. Cell survival in irradiated cells pre-treated with the PKC d
antisense oligonucleotide was statistically significantly reduced compared with the cells that
were pre-treated with the nucleotide scrambled version of the oligonucleotide. In conclusion,
PKC d depletion by antisense oligonucleotides impairs the survival of MDA-MB-231 human
breast tumor cells.
   To evaluate the effects of PKC d antisense oligonucleotide on the response of MCF-7 cells to a
therapeutic dose of g-radiation, MCF-7 cells pre-treated with PKC d antisense oligonucleotide
were exposed to 1.5 Gy radiation. Non-irradiated control cells were treated with PKC d antisense
oligonucleotide in parallel. The survival of MCF-7 cells treated with PKC d antisense
oligonucleotide was not reduced compared with liposome treatment alone (Figure 23B). PKC d
antisense oligonucleotide did not reduce MCF-7 cell survival post-1.5 Gy radiation. The
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discrepancy in the response of MCF-7 and MDA-MB-231 cells to PKC d antisense
oligonucleotide might be attributed to differences between the two cell types. In contrast to
MCF-7 cells, MDA-MB-231 cells are caspase-3 positive, p53 mutant, ER negative and have a
rapid proliferation rate. It is conceivable that inhibition of a survival factor such as PKC d wo ld
have a greater effect on the survival of rapidly proliferating cells like MDA-MB-231.
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Figure 23.  The effect of PKC d oligonucleotides and low dose g-radiation on the
survival of human breast tumor cells. (A) MDA-MB-231 cells were t ansfected with
PKC d oligonucleotides and 17 h later irradiated with 1.5 Gy g-radiation (IR), harvested
and replated (250 cells/well) in 96 well-plates. (B) MCF-7 cells were transfect d with
200 nM PKC d oligonucleotides and 48 h later irradiated with 1.5 Gy g-radiation,
harvested and replated (2500 cells/well) in 96 well-plates. MTS activity was measured
after 5 (A) or 7 (B) days as an index of survival. The survival of uni radiated control cells
was set =100%. Data are the mean ±SE of n=4 (A) or n=3 (B) independent experiments
performed with 5 replicates/treatment. Statistically significant differences between the
oligonucleotide treatments are indicated (*P <0.05).
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2.8 Expression of PKC d Dominant Negative Impaired MCF-7 Cell Survival. To determine
if inhibition of PKC d through an alternative approach could reduce MCF-7 survival, PKC d
dominant negatives were utilized. A point mutation was introduced into the full length coding
sequence of PKC d that produced a single amino acid substitution within the ATP binding
domain. Mutant PKC d was incorporated into a plasmid vector containing a neomycin resistance
gene and a cytomegalovirus promoter that yields high plasmid expression in human cells. This
mutation was sufficient to create a PKC d protein with dominant negative activity (Soh et al.,
1999).
   Transformed MCF-7 cells expressing the neomycin resistance gene were selected for by
growth in the presence of G418. The neomycin gene conferred resistance to G418 as evident by
visualization of MCF-7 cell colony formation (pcDNA3-neo) (Figure 24). In the absence of the
neomycin resistance gene, G418 acted as an 80S ribosome subunit inhibitor, interfered with
protein synthesis and was toxic to MCF-7 cells (“mock”). Transformation of MCF-7 cells with
PKC d dominant negative (pcDNA3-neo-PKCd dn) reduced visual colony numbers compared to
transformation with the plasmid vector alone. These results indicate that expression of a
dominant negative form of PKC d attenuates MCF-7 cell survival. Furthermore, these finding
support the hypothesis that PKC d functions as a survival factor in breast tumor cells.
Figure 24. MCF-7 cell transformation with PKC d dominant negatives. MCF-7 cells
(1x106/35 mm2  dish) were transfected with pcDNA3-neo, pcDNA3-neo-PKC d dnor “mock”
transfected. Post-transfection (72 h) culture medium was exchanged with DMEM/10% FBS
containing 400 mg/ml G418. After 18 days of growth in selection medium, cell colonies were
stained with crystal violet. Results are from a single experiment.
pcDNA3-neo pcDNA3-neo-PKCd dn
“mock”
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2.9 PKC d Oligonucleotide Treatment Resulted in Loss of DNA Integrity. Single cell gel
electrophoresis or “comet analysis” performed under alkali conditions permits sensitive and
quantitative analysis of single- and double-strand DNA damage (Fairbairn et al., 1995). The
electrophoretic mobility and relative intensity of fragmented nuclear DNA are incorporated into
the tail moment parameter. This assay was used to test the effects of PKC d oligonucleotide
treatment on cellular DNA. MDA-MB-231 cells were treated with PKC d oligonucleotides for
24-48 hours. Following this treatment, cells were exposed to g-radiation and immediately
prepared for comet analysis. Results are presented as frequency distribution of comet tail
moments in Figure 25A. In control cells the frequency of comets with tail moments less than 2
was 60%. These are representative of cells with undamaged nuclear DNA.  Treatment of MDA-
MB-231 cells with PKC d oligonucleotide caused the comet frequency distribution to shift
toward larger tail moments and this result is indicative of damaged DNA. The scrambled
nucleotide treatment did not result in increased DNA damage. Treatment with 1.5 Gy g-radiation
caused an increase in the frequency of tail moments greater than 2, similar to the effect of PKC d
oligonucleotide treatment. The combination of PKC d oligonucleotide and radiation produced a
further increase in the number of comets displaying DNA damage.  Similar effects on the comet
tail moments were observed when cells were analyzed 48 hours after treatment with PKC d
oligonucleotide (Figure 25B).
   Table 5 summarizes the comet analysis results for 24 and 48 hours after treatment of MDA-
MB-231 cells with PKC d oligonucleotide. The percentage of comets with tail moments greater
than 2 and greater than 20 are shown. Tail moments of greater than 2 are an index of all DNA
damage, while tail moments greater than 20 are an index of severe DNA damage. These
experiments provide evidence that reduced cell survival by depletion of PKC d is acc mpanied
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by a loss of DNA integrity. Furthermore, PKC d oligonucleotide treatment alone is sufficient to
produce DNA damage in the absence of radiation treatment. It is possible that PKC d
oligonucleotide treatment directly damages DNA, but this is difficult to reconcile with the
observation that the scrambled oligonucleotide is inactive at causing DNA damage. Rather, it is
hypothesized that PKC d is involved in pathways regulating genome integrity or during DNA
synthesis. Furthermore, we hypothesize that PKC d lso contributes to the repair of DNA
following DNA damage.
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Figure 25A. Comet analysis of MDA-MB-231 cells treated with PKC d
oligonucleotide +/- radiation. MDA-MB-231 cells (1.1x105/35 mm2 dish) were treated
with nothing (control), lipofectin (L), scrambled oligonucleotide (SCR) or PKC d
oligonucleotide (PKCd). Following transfection (24 h), cells were irradiated (1.5 Gy IR)
and prepared for comet analysis. The number of comets with tail moments in ranges
between 0-2, 5-10, 10-20, 20-50, 50-100 and >100 are plotted for each treatment group.
Data represent n=3 independent experiments with 80 comets scored per
treatment/experiment. Statistically significant differences are indicated below (*P<0.05).
Statistical Analyses (ANOVA)
Comparison                                                             P Value
*Control, L and SCR vs. PKCd                               <0.05
*Control, L, SCR and PKCd
  vs. IR, L+IR, SCR+IR and PKCd+IR                    <0.05
*IR and SCR+IR vs. PKCd +IR                              <0.05
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Figure 25B. Comet analysis of MDA-MB-231 cells treated with PKC d
oligonucleotide +/- radiation. MDA-MB-231 cells (1.1x105/35 mm2 dish) were treated
with nothing (control), lipofectin (L), scrambled oligonucleotide (SCR) or PKC d
oligonucleotide (PKCd). Following transfection (48 h), cells were irradiated (1.5 Gy IR)
and prepared for comet analysis. The number of comets with tail moments in ranges
between 0-2, 5-10, 10-20, 20-50, 50-100 and >100 are plotted for each treatment group.
Data represent n=3 independent experiments with 80 comets scored per
treatment/experiment. Statistically significant differences are indicated below (*P<0.05).
Statistical Analyses (ANOVA)
Comparison                                                             P Value
*Control, L and SCR vs. PKCd                               <0.05
*Control vs. PKCd+IR                                             <0.05
*L vs. IR, L+IR and PKCd+IR                                <0.05
*SCR vs. PKCd+IR                                                 <0.05
*IR, L+IR and SCR+IR vs. PKCd +IR                    <0.05
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Control 39.6%, 2.5% 38.3%, 10.0%
scr 32.5%, 5.8% 32.5%, 7.9%
PKC d 60.4%, 16.3% 54.6%, 23.3%
IR 60.4%, 17.9% 58.3%, 21.7%
scr+IR 59.2%, 17.1% 39.2%, 10.0%
PKC d+IR 70.4%, 27.1% 70.0%, 28.3%
24h 48h
Tail Moment:     >2,    >20                >2,    >20
Table 5. Comet analysis summary. Data summarized are comet assay results obtained
in MDA-MB-231 cells treated with PKC d oligonucleotide for 24 and 48 hours after
treatment (Figure 25). Data are presented as fraction comets with tail moments greater
than 2 and greater than 20.
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2.10 PKC Isoform Expression MCF-7 and MCF-10A Cell Lines. MCF-10A cells are an
immortalized cell line derived from normal mammary epithelium. The expression of individual
PKC isoforms in normal versus tumor mammary epithelial cells was of interest. Western blot
analyses of MCF-7 and MCF-10A whole cell extracts were performed and the relative levels of
PKC a, PKC d, PKC e, PKC z and bcl-2 were compared.  Neither MCF-7 nor MCF-10A
expressed immunodetectable PKC a (Figure 26). In contrast, MDA-MB-231 mammary tumor
epithelial cells overexpress PKC a (Figure 6). PKC d, PKC e and PKC z were detected in MCF-
7 and MCF-10A cells. Bcl-2 protein expression levels presented the most striking difference
between the two cell lines. The anti-apoptotic bcl-2 protein was detected at a greater intensity in
MCF-7 cell extracts than in extracts from MCF-10A cells. These findings demonstrate that in
contrast to normal mammary cells, breast cancer cells contain increased PKC isoform and bcl-2
protein expression.
STD
PKC a
PKC d
Bcl-2
PKC e
PKC z
MCF-
Figure 26.  PKC protein levels in MCF-7 and MCF-10A cells. Whole cell extracts
were prepared from MCF-7 (7.5x105) or MCF-10A (1.0x106) cells/100 mm2 dish 24 h
post-subculture from confluency. Proteins (40 mg/lane- a, d, e, bcl-2 and 20 mg/lane- z)
were resolved on 7.5% polyacrylamide gels, transferred to filters and probed with
antibodies to PKC a, PKC d, PKC e, PKC z and bcl-2. The PKC standards (STD)
included purified PKC a (15 ng/lane), PKC d (20 ng/lane), PKC e (4 ng/lane) and PKC z
(25 ng/lane). Data shown are typical of n=2 experiments.
7 10A
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2.11 Treatment of Normal Mammary Cells with PKC d Oligonucleotides. The finding that
PKC d antisense oligonucleotide treatment reduced the survival of breast tumor cells provided a
rational to test the effects of this oligonucleotide in normal mammary cells. Neither the
nucleotide scrambled sequence of PKC d oligonucleotide nor lipofectin alone produced a
reduction in MCF-10A cell survival (Figure 27). While the difference was not statistically
significant, MCF-10A cells treated with PKC d antisense oligonucleotide displayed reduced
survival compared to treatment with the nucleotide scrambled sequence. The magnitude of the
reduction was less than that observed in MDA-MB-231 cells treated with PKC d antisense
oligonucleotide (Figure 23A). These results indicate that the growth inhibitory effects of PKC d
depletion by oligonucleotides are not limited to breast tumor cells. However, breast tumor cells
exhibited greater sensitivity to PKC d antisense oligonucleotide treatment than normal mammary
cells.
   In addition, the effects of g-radiation on MCF-10A cell survival were evaluated. In response to
1.5 Gy irradiation survival was reduced by approximately 5%, while 5.2 Gy irradiation reduced
survival by 50%. The reduction in cell survival by radiation in MCF-10A cells was similar to
that seen in MCF-7 and MDA-MB-231 cell lines, indicating that these normal cells do not have
an increased sensitivity to radiation in comparison to the two tumor cell lines tested.
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Figure 27. MCF-10A cell survival in response to PKC d oligonucleotide or g-
radiation treatment. MCF-10A cells were treated with 100 nM PKC d oligonucleotide
plus liposome (PKCd). Controls were treated with no treatment (C), liposome alone (L),
liposome plus scrambled nucleotide sequence of the PKC d oligonucleotide (SCR) or
radiation alone (1.5 Gy or 5.2 Gy). Post-ransfection (24 h), cells were harvested and
replated in 96-well plates at a cloning density of 250 cells/well. After 5 days of
incubation, cell survival was estimated using the MTS assay. Data are the mean ±SE of
n=3 independent experiments performed with 5 replicates/treatment. Survival of control
cells was set =100%. There were no statistically significant differences between groups
treated with PKC d antisense oligonucleotide versus nucleotide scrambled PKC d
oligonucleotide (SCR) (P<0.05).
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Chapter 3. PKC z is a Pro-survival Factor.
3.1 Survival of Breast Tumor Cells Treated with PKC z Antisense Oligonucleotides and
Radiation. PKC z has been cited by numerous independent studies to promote cell proliferation
and survival (Introduction 8.11). Consistent with these reports, MDA-MB-231 cell survival in
response to radiation was significantly decreased by pre-treatment with PKC z antisense
oligonucleotides compared to pre-treatment with the nucleotide scrambled sequence
oligonucleotide (P<0.05) (Figure 28A). In this pair of oligonucleotides, the nucleotide scrambled
version of PKC z (SCR) reduced cell survival compared to liposome treatment alone, indicating
these sequences exert some non-specific effects on cell survival. PKC z anstisense
oligonucleotide resulted in a marked overall decrease in cell survival of irradiated cells from
91% (liposome treatment alone) to 32% (liposome plus PKC z antisense oligonucleotide). In
conclusion, both PKC z antisense and nucleotide scrambled sequence oligonu leotides induce
tumor cell death in response to radiation. The mechanism of this response is explored in more
detail in subsequent experiments (Figures 31 and 33).
   In MCF-7 cells, as noted previously, liposome treatment alone significantly impaired cell
survival (Figure 28B). PKC z antisense oligonucleotide treatment did however, significantly
reduce the survival of irradiated MCF-7 cells in comparison to treatment with the nucleotide
scramble sequence oligonucleotide (SCR). Because the scrambled sequence oligonucleotide did
not affect MCF-7 cell survival, the specific effects of the PKC z antisense oligonucleotide may
be distinguished from non-sequence specific effects. These results confirm the participation of
PKC z in the survival of radiation treated breast tumor cells.
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Figure 28. Cell survival in response to g-radiation +/- PKC z oligonucleotide
treatment. (A) MDA-MB-231 cells (1.1x105/35 mm2 dish) 24 h post-subculture from
confluency were transfected with liposome plus 100 nM PKC z antisense (PKCz) or
scrambled sequence oligonucleotide (SCR) plus liposome. Controls received either no
treatment or liposome (L) alone. Post-transfection (24 h), cells were irradiated (IR) with
5.6 Gy of g- radiation, harvested and replated in 96-well plates at a cloning density of 250
cells/well. After 5 days of incubation, cell survival was estimated using the MTS assay.
(B) MCF-7 cells (2.2x105/35 mm2 dish) 24 h post-subculture from confluency were
transfected with liposome plus 200 nM PKC z antisense (PKCz) or scrambled sequence
oligonucleotide (SCR) plus liposome. Controls were as described above. Post-
transfection (48 h), cells were irradiated with 5.6 Gy g-radiation 48 h post-transfection,
harvested and replated in 96-well plates at a cloning density of 2500 cells/well. After 7
days of incubation, cell survival was estimated using the MTS assay. Data are the mean
±SE of n=4 (A) or n=3 (B) independent experiments performed with 5
replicates/treatment. Survival of cells treated with radiation alone was set =100%.
Statistically significant differences between PKC a tisense oligonucleotide treatment
versus nucleotide scrambled sequence PKC oligonucleotide (SCR) treatment are
indicated (*P<0.05).
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3.2 Treatment of Breast Tumor Cells with the Combination of Low Dose g-radiation and
PKC z Oligonucleotide. To evaluate the ability of PKC z antisense oligonucleotide to reduce
cell viability in response to a therapeutically relevant dose of radiation, experiments were
performed using cells treated with 1.5 Gy radiation. MDA-MB-231 cell survival was impaired
by treatment with either the isoform specific (PKCz) or nucleotide scrambled version (SCR) of
the PKC z antisense oligonucleotide (Figure 29A). There was no statistically significant
difference in survival of cells treated with the PKC z antisense oligonucleotide versus the
scrambled nucleotide version. In MCF-7 cells, survival was attenuated by treatment with
liposome or PKC z oligonucleotide (Figure 29B), but there was no statistically significant
reduction in survival in MCF-7 cells treated with the PKC z antisense oligonucleotide versus the
scrambled sequence oligonucleotide.
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Figure 29.  The effect of PKC z oligonucleotides on cells treated with low dose g-
radiation. (A) MDA-MB-231 cells (1.1x105/35 mm2 dish) 24 h post-subculture from
confluency were transfected with 100 nM PKC z oligonucleotides and 17 h later
irradiated with 1.5 Gy g-radiation (IR), harvested and replated (250 cells/well) in 96 well-
plates. MTS activity was measured after 5 days as an index of survival. (B) MCF-7 cells
(2.2x105/35 mm2 dish) 24 h post-subculture from confluency were treated with 200 nM
PKC z oligonucleotides and 48 h later irradiated with 1.5 Gy g-radiation, harvested and
replated (2500 cells/well) in 96 well-plates. MTS activity was measured after 7 days as
an index of survival. Data are the mean ±SE of n=4 (A) or n=3 (B) independent
experiments performed with 5 replicates/treatment. Survival of cells treated with
radiation alone was set =100%. There were no statistically significant differences
between the PKC z antisense and scrambled sequence oligonucleotide treatments (P
<0.05).
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3.3 PKC z Protein Levels in PKC z Oligonucleotide Treated Cells. To test whether PKC z
antisense oligonucleotide treatment resulted in reductions in PKC z protein levels, western blot
analyses were conducted using extracts prepared from MCF-7 cells 48 hours after PKC z
antisense oligonucleotide treatment. PKC z antisense oligonucleotide treatment caused a 50%
reduction in PKC z protein level and neither liposome alone nor the nucleotide scrambled
version (SCR) of the oligonucleotide had an effect on the PKC z protein levels (Figure 30A).
   PKC z protein levels were examined in extracts prepared from MDA-MB-231 cells 24 hours
after treatment with PKC z oligonucleotide. PKC z protein levels were reduced by PKC z
antisense oligonucleotide treatment  (Figure 30B). Liposome alone or control oligonucleotide did
not affect PKC z protein levels in MDA-MB-231 cells. These results indicate that the reduction
in cell survival by the nucleotide scrambled version of this oligonucletide (Figures 28A and 29A)
was not due to a depletion of PKC z protein. It is possible that this oligonucleotide manifests
non-sequence specific activity on cellular factors, which influence survival such as those
previously described (Introduction 9.2). Alternatively, the scrambled nucleotide sequence might
act as an antisense olignucleotide on another target mRNA species within the MDA-MB-231
cells and absent from MCF-7 cells.
   The magnitude of the reduction by the PKC z oligonucleotide was less in MDA-MB-231 cells
than in MCF-7 cells and is likely due to the lower antisense oligonucleotide concentration (50
nM) and shorter incubation time of 24 hours between oligonucleotide treatment and extract
preparation. Perhaps, a greater reduction would have been observed in extracts prepared 48 hours
after 100 nM PKC z oligonucleotide treatment. Immunodetection of PKC z in MCF-7 and
MDA-MB-231 cells confirm that PKC z oligonucleotide is an inhibitor of PKC z protein and
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support that reduced MCF-7 cell survival by PKC z antisense oligonucleotide involves PKC z
protein reduction.
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Figure 30. PKC z protein levels in PKC z oligonucleotide treated cells. (A) Extracts
were prepared from MCF-7 cells 48 h after treatment with lipofectin alone (L), 100 nM
PKC z antisense oligonucleotide (PKCz), the nucleotide scrambled version (SCR) or no
treatment (C). Proteins (45 mg/lane) were resolved on 7.5% polyacrylamide gels,
transferred to filters and probed with an antibody to PKC z. Control signal density was
set =100%. Signal densities were normalized to a 200 kDa protein band on the
Coomassie blue-stained acrylamide gel. Data in graph are the mean ±SE of n=3
independent experiments. Statistically significant differences between treatment groups
receiving PKC z oligonucleotides versus nucleotide scrambled sequence of PKC z
oligonucleotides are indicated (*P<0.05). Blot is typ cal of n=3 independent experiments.
(B) Protein extracts (55 mg/lane) were prepared from MDA-MB-231 cells 24 h after
treatment with lipofectin alone (L), 50 nM PKC z oligonucleotide (PKCz), the nucleotide
scrambled version (SCR) or no treatment (C). Results are from a single experiment.
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3.4 PKC z Protein Levels in MCF-7 Cells Following Exposure to Ionizing Radiation. To
determine if PKC z protein level elevation is a response to g-radiation treatment, PKC z protein
levels were examined following exposure to 5.2 Gy radiation. Extracts prepared from MCF-7
cells at either 3 or 21 hours after radiation exposure showed constant levels of PKC z prot in
(Figure 31). Previous experiments evidenced that PKC z is a survival factor in breast tumor cells.
The observation that PKC z protein levels are unaltered in response to radiation suggests that
changes in PKC z enzyme activity may be occurring as a response to radiation exposure.
Time Post-IR (hours)
3 h 21 h
PKC z
50KD
No IR  5.2GyIR No IR  5.2GyIR
Figure 31. PKC z protein levels in MCF-7 cells following exposure to ionizing
radiation. Whole cell extracts were prepared from MCF-7 cells 3 h and 21 h after
exposure to 5.2 Gy radiation. Proteins (30 mg/lane) were resolved on 7.5% acrylamide
gels, transferred to filters and probed with an antibody to PKC d. A Coomasie blue-
stained protein is shown as the loading control. Data shown are representative of n=2
independent experiments.  
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3.5 Expression of PKC z Dominant Negative Inhibited MCF-7 Cell Survival.  For further
confirmation that inhibition of PKC z abrogates cell survival, MCF-7 cells were transformed
with a dominant negative form of PKC z. As described previously (Results 2.8), dominant
negative PKC species were generated by introducing a point mutation into the ATP binding
domain. MCF-7 cells expressing the neomycin resistance gene were selected for by the addition
of G418 to the culture medium. The product of the neomycin resistance gene is an
aminoglycoside phosphotransferase that inactivates G418 and confers cellular resistance.
Following 18 days of growth in the presence of G418, the survival of MCF-7 cells transformed
with the neomycin resistance gene is evidenced by colony formation (Figure 32). Colony
formation was inhibited if MCF-7 cells were transformed with the PKC z dominant negative
(pcDNA3-neo-PKCz dn) in comparison to MCF-7 cells transformed with vector alone
(pcDNA3-neo). “Mock” transfected MCF-7 cells were not able to survive in the presence of
G418. We conclude that PKC z is a survival factor in breast tumor cells and that inhibition of
PKC z reduces MCF-7 cell survival. These results are consistent with previous findings that
PKC z antisense oligonucleotide reduced MCF-7 cell survival (Figures 28B and 29B).
Figure 32. MCF-7 cell transformation with PKC z dominant negatives. MCF-7 cells
(1x106/35 mm2  dish) were transfected with pcDNA3-neo, pcDNA3-neo-PKCz  dn or “mock”
transfected. Post-transfection (72 h) culture medium was exchanged with DMEM/10% FBS
containg 400mg/ml G418. After 18 days of growth in selection medium, cell colonies were
stained with crystal violet. Results are from a single experiment.
pcDNA3-neo pcDNA3-neo-PKCz dn
“mock”
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3.6 DNA Damage Analysis Following PKC z Oligonucletide Treatment. To analyze the
effects of PKC z depletion on DNA integrity in MDA-MB-231 cells, PKC z antisense
oligonucleotide was added. Following treatment (24 hours), cells were exposed to 1.5 Gy
radiation and prepared for comet analysis. Neither PKC z antisense oligonucleotide nor the
scrambled nucleotide control (SCR) produced significant DNA damage in MDA-MB-231 cells
as measured by the tail moment parameter (Figure 33). Exposure to 1.5Gy g-radiation did
produce significant increases in the frequency of comets containing damaged DNA. The
combination of PKC z antisense oligonucleotide and 1.5 Gy radiation did not increase DNA
damage greater than radiation alone. In conclusion, PKC z antisense oligonucleotide treatment
did not affect DNA integrity in MDA-MB-231 cells.
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Figure 33. Comet analysis of MDA-MB-231 cells treated with PKC z oligonucleotide
+/- radiation. MDA-MB-231 cells (1.1x105/35 mm2 dish) were treated with lipofectin
alone (Control), scrambled o igonucleotide (SCR) or PKC z antisense oligonucleotide
(PKCz). Following treatment (24 h), cells were treated with 1.5 Gy radiation (IR) and
prepared for comet analysis. The number of comets with tail moments in ranges between
0-2, 2-5, 5-10, 10-20, 20-50, 50-100 and >100 were plotted for each treatment group.
Data represent n=3 independent experiments with 80 comets scored per
treatment/experiment. Statistically significant differences are indicated below (*P<0.05).
Statistical Analyses (ANOVA)
Comparison                                                             P Value
*Control, SCR and PKCz
 vs. IR, SCR+IR and PKCz+IR                                <0.05
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3.7 Treatment of Normal Mammary Cells with PKC z Oligonucleotides. To test if the
growth inhibitory effects of PKC z antisense oligonucleotide are restricted to breast tumor cells,
normal mammary tumor cells were treated with PKC z oligonucleotides. Treatment of MCF-10A
cells with PKC z antisense oligonucleotide produced no specific reduction in survival compared
to treatment with the scrambled sequence oligonucleotide (Figure 34). Non-specific effects were
evident by the impairment of survival in MCF-10A cells treated with the scrambled nucleotide
version of the PKC z oligonucleotide. The PKC z oligonucleotide did however, reduce survival
relative to treatment with liposome alone. While these results do not separate sequence specific
from non-sequence specific effects of the PKC z oligonucleotides, they do show that the survival
of normal mammary cells is affected by PKC z olgionucleotide treatment.
Figure 34. MCF-10A cell survival in response to PKC z oligonucleotide treatment.
MCF-10A cells were treated with 100nM PKC z oligonucleotide plus liposome (PKCz).
Controls were treated with no treatment (C), liposome alone (L) or  liposome plus a
scrambled nucleotide sequence of the PKC z oligonucleotide (SCR). Post-transfection
(24 h), cells were harvested and replated in 96-well plates at a cloning density of 250
cells/well. After 5 days of incubation, cell survival was estimated using the MTS assay.
Data are the mean ±SE of n=3 independent experiments performed with 5
replicates/treatment. Survival of control cells was set =100%. There were no statistically
significant differences between groups treated with PKC z antisense oligonucleotide
versus nucleotide scrambled PKC z oligonucleotide (SCR) (P<0.05).
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IV. DISCUSSION
   Protein kinase C (PKC) participates in a variety of cellular processes. Of importance to this
discussion is the role that PKC plays in cancer. As a regulator of signal transduction pathways
which control cell proliferation and death and as the primary intracellular receptor for tumor
promoting phorbol esters, PKC represents a potentially important molecular target for anti-
cancer therapeutics. PKC is a family of serine/threonine kinases composed of twelve unique
isoforms. Since the discovery of PKC more than 20 years ago, studies are only recently revealing
the functions of individual PKC isoforms. Thus far, the roles of PKC isoforms in cancer have
proven to be complex and often contradictory. Conclusions on the functions of individual PKC
isoforms must be assigned within their appropriate cell contexts as many of their functions are
cell-type specific.
    Relatively little information exists pertaining to the functions of individual PKC isoforms in
breast cancer. However, PKC has previously been shown to have increased activity and
expression in breast cancer versus normal mammary tissue (O’Brian et al., 1989; Gordge et al.,
1996). The present study was aimed at identifying specific PKC isoforms that facilitate breast
tumor cell survival. Gamma radiation was used to challenge survival of the breast tumor cells in
these studies because the results of earlier experiments with the PKC inhibitors, staurosporine,
sangivamycin and H7 provided evidence that PKC activation was radioprotective (Begemann et
al., 1998; Hallahan et al., 1992; Zhang et al., 1993). Our preliminary results showed that specific
inhibition of PKC d and PKC z suppressed the survival of two radiation treated breast tumor cell
lines. Subsequent studies provided evidence that in the absence of radiation treatment, PKC d
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and PKC z antisense oligonucleotides reduced cell survival. Hence, PKC d and PKC z isoform
antagonists are not radiosensitizers, but are inhibitors of survival.
   The main approaches to i of rm selective PKC inhibition are site selective enzyme inhibition
or suppression of the mRNA levels. Oligonucleotides that target RNA are highly specific PKC
isoform antagonists, and may be easier and less expensive to synthesize than traditional small
molecule inhibitors targeted to the enzyme. A few small molecule inhibitors offer PKC isoform
specific inhibition. The small molecule inhibitor, rottlerin, is selective for the PKC d isoform
(IC50 3-6 mM) but also inhibits calmodulin kinase III (IC50=5.3 mM) (Way et al., 2000).
Alternatively, one other approach to isoform selective PKC inhibition is through the use of
dominant negatives. PKC d and PKC z coding sequences containing mutations within the ATP
binding domains encode PKC proteins with dominant negative inhibitory activity on wild-type
PKC d and PKC z, respectively (Soh et al., 1999). Our approach to elucidate the role of
particular PKC isoforms involved in mammary tumor cell survival following radiation has been
to use antisense oligonucleotides, dominant negatives and where possible, small molecule
inhibitors.    
    The experiments performed in this project using PKC a tisense oligonucletides were
complicated by some non-specific effects. Delivery of the PKC ligonucleotides was mediated
by the cationic liposome, Lipofectin. MCF-7 cells in particular were highly sensitive to treatment
with the lipid carriers and exhibited reduced survival as a consequence (Figure 8). The nature of
liposome mediated toxicity has been investigated previously and was reported to involve the
generation of reactive oxygen intermediates. Examination of cellular toxicity produced by
liposomes showed a positive correlation between the net positive charge of the liposom and
toxicity. Cationic liposomes triggered the generation of reactive oxygen intermediates in a
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charge and dose-dependent manner (Dokka et al., 2000).  These findings provide a possible
explanation for the reduction in MCF-7 cell survival observed in response to liposome treatment,
but do not account for the differences in sensitivity to liposomes observed between MCF-7 and
MDA-MB-231 cells. Perhaps differences in anti-oxidant capabilities of these two cell lines exist
to explain this difference. PKC oligonucleotide delivery in the absence of liposome was
attempted but was not an effective method in either cell type (Figure 9).
   PKC oligonucleotides also displayed some non-sequence specific activity on cell survival.
Sequence specific effects of antisense oligonucleotides are those effects due solely to the
depletion of the targeted mRNA. Conversely, non-sequence specific effects are those due to
oligonucleotide interference with cellular components (mRNA or protein) other than their
specific targets. Non-sequence specific activities are inherent problems with oligonucleot des
and are thought to be a consequence of the chemical modifications required for nuclease
resistance (Nielson, 1999). In the case of PKC z oligonucleotides, the non-sequence specific
effects observed on cell survival (Figure 7, 28A, 29A) were not manifested as alterations of PKC
z protein levels (Figure 30) indicating that the scrambled sequence oligonucl otide was affecting
a cellular factor other than PKC z. PKC oligonucleotides were effective and specific inhibitors of
target protein expression, while control scrambled sequence oligon cleotides had no effect on
PKC protein expression levels (Figures 18 and 19). Certain antis nse oligonucleotides, such as
PKC d, exhibited only sequence specific effects on cell survival while the scrambled nucleotide
sequence had no influence on survival (Figures 7, 17 and 23).
   Several studies have correlated overexpression of the a PKC isoform with more aggressive
breast tumor cell phenotypes, such as estrogen receptor-negative and multi-drug resistant
phenotypes (Ways et al., 1995; Yu et al., 1991). Comparisons of PKC isoform content between
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different breast tumor cell types supported these findings. MDA-MB-231 cells, which are
estrogen receptor-negative and tumorgenic, displayed markedly higher levels of PKC a than the
estrogen receptor-positive, non-tumorogenic MCF-7 cells (Figures 6 and 16). In fact, previous
studies have shown that transformation of MCF-7 cells with PKC a results in loss of estrogen
receptors, enhanced proliferation, anchorage-independent growth and increased tumorogenicity
(Ways et al., 1995). These findings provided a rational to test whether PKC a inhibition would
reduce cell survival. As expected, PKC a antisense oligonucleotide impaired survival in
radiation treated MDA-MB-231 cells, but not in MCF-7 cells relative to liposome treatment
(Figures 7 and 8). However, the scrambled nucleotide control sequence reduced survival to the
same extent as the PKC a antisense oligonucleotide. In subsequent experiments utilizing a
different sequence, the effect of nucleotide scrambled control was persistent. The non-specific
activity of the control sequence on ll survival prevented conclusions regarding sequence
specific activity of PKC a antisense oligonucleotide on cell survival.
   MCF-10A are an immortalized, non-transformed and non-tumorgenic cell line. Other studies
have shown that stable transformation of MCF-10A with PKC a resulted in increased motility
and adhesion, characteristics consistent with a metastatic phenotype (Sun and Rotenberg, 1999).
Our findings confirm the absence of PKC a expression in MCF-10A cells (Figure 26). In
addition, MCF10A cells express reduced levels of all PKC isoforms tested when compared to
MCF-7 cells, indicating that increased PKC protein levels in breast tumor cells may be a
deviation from the PKC protein content of normal mammary cells.
   MCF-10A cells were further utilized to examine the effects PKC d and PKC z oligonucleotides
on non-tumorogenic mammary cells. Ideally, anti-cancer therapeutics should be tumor selective.
Treatment of MCF-10A normal mammary cells with PKC d antisense oligonucleotide (Figure
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27) indicated that these cells were less sensitive to PKC d inhibition than the umorgenic MDA-
MB-231 cells (Figure 23). Treatment of MCF-10A cells with PKC z antisense oligonucletide did
not produce any distinguishable sequence specific effects on cell survival (Figure 34). To reduce
the effects of PKC oligonucleotides on normal mammary cells a tumor t rgeted delivery system
for PKC oligonucleotides might be advantageous. The receptor tyrosine kinase, Her-2/neu, is
overexpressed in a significant number of breast cancers and associated with poor prognosis. Her-
2/neu presents a unique target that may be exploited for tumor selective therapy. Liposomes
conjugated to Her-2/neu monoclonal antibodies that target Her-2/neu positive breast tumor cells
offer an example of a targeted delivery system (Hong et al., 1999). This type of approach may be
useful in future studies with PKC antisense oligonucleotides.
   In conclusion, the present study showed that selective inhibition of the PKC d and PKC z
isoforms through the use of antisense oligonucleotides, small molecule inhibitors and dominant
negatives decreased human mammary tumor cell survival. Coinciding with reduced cell survival,
PKC d depletion by antisense oligonuncleotide caused an increase in cells containing damaged
DNA (Figure 25). Cell death (necrosis) was evidenced by propi ium iodide uptake following
treatment (24-48 hours) with the PKC d inhibitor, rottlerin. These findings suggest that PKC d
and PKC z positively regulate survival in breast cancer cells. This work begins to clarify the role
of individual PKC isoforms that mediate breast tumor cell survival. Additional work is needed to
elucidate the cell death pathways that are regulated by PKC d and PKC z.
   The clinical success of ISIS 3521, a PKC a antisense oligonucleotide, in solid tumor treatment
illustrates the importance of PKC isoforms as anti-cancer therapeutic targets (Nemunaitis et al.,
1999). Overall, our findings support the use of tumor targeted PKC ntisense oligonucleotides to
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breast tumors. Furthermore, the expansion of isof rm selective PKC inhibitors to other tumor
types will be a valuable application in the future development of novel anti-cancer therapeutics.
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